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Abstract 
Tomato consumption has been correlated with decreased risks of chronic diseases 
like prostate cancer and cardiovascular disease. Among many nutrients and 
phytochemicals in fresh tomatoes and tomato products, carotenoids are thought to be the 
bioactive components responsible for disease prevention. Many epidemiological studies, 
clinical trials, animal studies, and in vitro studies have focused on the most abundant 
tomato carotenoid, lycopene. However, the absorption, distribution and metabolism of 
phytoene and phytofluene, the precursors of lycopene and the 2nd- and the 3rd-most 
abundant tomato carotenoids, have not been fully studied. With the discovery of the 
human carotenoid cleavage enzymes carotene-15’,15’-monooxygenase (CMO-I) and 
carotene-9’,10’-monooxygenase (CMO-II), enzymatic degradation is proposed to be a 
mechanism of tomato carotenoid metabolism. In order to elucidate the metabolism and 
excretion routes of absorbed tomato carotenoids, a tracer system must be established to 
assist in locating the parent molecules, identifying metabolic products and potentially 
calculating kinetics/dynamics models. 
A tomato cell suspension culture system for the production of radioisotope-
labeled lycopene was previously developed in our laboratory. The first section of this 
research was to optimize the lycopene extraction efficiency from tomato cell cultures for 
preparatory HPLC separation. We employed response surface methodology (RSM), 
which combines fractional factorial design and a second-degree polynomial model. 
Tomato cells were homogenized with ethanol, saponified by KOH, extracted with 
hexane, and the lycopene content was analyzed by HPLC-PDA. We varied five factors at 
five levels: ethanol volume (1.33-4 mL/g); homogenization period (0-40 s/g); saturated 
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KOH solution volume (0-0.67 mL/g); hexane volume (1.67-3 mL/g); and vortex period 
(5-25 s/g). Ridge analysis by SAS suggested that the optimal extraction procedure to 
extract 1 g of tomato cells was at 1.56 mL ethanol, 28 s homogenization, 0.29 mL KOH, 
2.49 mL hexane and 17.5 s vortex. These optimal conditions predicted by RSM were 
confirmed to enhance lycopene yield from standardized tomato cell cultures by more than 
three fold. 
Furthermore, a bioengineered Escherichia coli model for the laboratory-scale 
production of stable isotope-labeled carotenoids was developed.  Carotenoid biosynthetic 
genes from Enterobacter agglomerans were introduced into the BL21Star(DE3) strain to 
yield lycopene.  Over 96% of accumulated lycopene was in the all-trans isoform, and the 
molecules were highly enriched with 13C by 13C-glucose dosing. In addition, error-prone 
PCR was used to create a phytoene-accumulating strain, which maintained the 
transcription of phytoene synthase (crtB). Phytoene molecules were also highly enriched 
with 13C when 13C-glucose was the only carbon source.  The development of this 
production model will provide carotenoid researchers a source of labeled materials and to 
further investigate the metabolism and biological functions of these carotenoids. 
To date, there is no experimental evidence to demonstrate the biological function 
of human CMO-II; therefore, Escherichia coli was selected to express this enzyme. The 
full-length human CMO-II sequence and a truncated CMO-II sequence were expressed, 
but the expressed proteins were insoluble. Tagging with NusA did not improve its 
solubility. E. coli strain Origami 2 and co-expression of CMO-II with chaperonins were 
also used to provide a protein-folding friendly environment, but the majority of CMO-II 
remained insoluble. Furthermore, denaturation, purification and refolding procedures 
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were used to rescue CMO-II, but the refolded enzymes did not degrade the carotenoid 
substrate lutein. In conclusion, other expression hosts rather than E. coli might be better 
platforms to express soluble human CMO-II and further elucidate its role in carotenoid 
metabolism. 
Overall, this research explored suitable production systems to produce 
isotopically labeled carotenoids and piloted the expression of the human enzyme CMO-II 
in E. coli. With the tools developed in this research, soon we will be able to discover the 
details of the metabolism of tomato carotenoids and further improve the human health. 
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CHAPTER 1: 
Literature Review 
 
Introduction 
Tomato consumption has been correlated with decreased risks of chronic diseases 
like prostate cancer and cardiovascular disease 1. Among many nutrients and 
phytochemicals in fresh tomatoes and tomato products, carotenoids are thought to be the 
bioactive components responsible for disease prevention. Many epidemiological studies, 
clinical trials, animal studies and in vitro studies have focused on the most abundant 
tomato carotenoid, lycopene 2. However, the absorption, distribution and metabolism of 
phytoene and phytofluene, the precursors of lycopene and the 2nd - and the 3rd – most 
abundant tomato carotenoids, have not been fully studied. With the discovery of the 
human carotenoid cleavage enzymes CMO-I and CMO-II 3, enzymatic degradation is 
proposed to be a mechanism of tomato carotenoid metabolism. 
In order to elucidate the metabolism and excretion routes of absorbed tomato 
carotenoids, a tracer system must be established to assist locating the parent molecules, 
identifying metabolic products, and potentially calculating kinetics/dynamics models. 
Although methods for industrial carotenoid production, complete chemical synthesis or 
algae extraction, have been established, these methods are focused on producing 
commercial carotenoids like beta-carotene and astaxanthin; even small quantities of fine 
chemicals, like isotopically labeled carotenoids, are not commercially available at this 
moment to carotenoid researchers. Therefore, a laboratory-scale labeled-carotenoid 
production system needs to be developed and applied to the biomedical research. This 
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chapter will summarize the major and current advances in this field and provide a 
foundation to the research presented in this dissertation. 
 
Tomato consumption prevents chronic diseases in humans 
Tomato production and consumption in the United States. According to the 
Food and Agriculture Organization of the United Nations, the United States is one of the 
world’s leading producers of tomatoes (12.7 million US tons in 2008), second only to 
China. In the United States, the tomato was the second most popular fresh-market 
vegetable behind potatoes in 2010. Fresh and processed tomatoes account for more than 
$2 billion in annual farm cash receipts. Annually, the average American consumes 20.8 
pounds of fresh tomatoes (Lycopersicon esculentum) and 71 pounds of processed tomato 
products. About 35% of raw tomatoes are processed into sauces, 18% into tomato paste, 
17% into canned whole tomato products, 15% into ketchup and 15% into juice 4. 
Tomato consumption and prostate cancer: epidemiological studies. In a meta-
analysis of observational studies (11 case-control and 10 cohort studies), high versus low 
intake of tomatoes was associated with an approximate 10-20% reduction in risk for 
prostate cancer 5. In general, results from case-control studies have not supported a 
protective effect of lycopene or tomato products on prostate cancer risk, whereas cohort 
studies of dietary factors and incident prostate cancer have been more supportive. 
Two large cohort studies conducted in the United States evaluated tomato and/or 
tomato sauce intake and prostate cancer risk 6,7. Giovannucci et al. 6 followed 47,365 men 
in the Health Professionals Follow-Up Study cohort for approximately 12 years, during 
which time 2,481 cases of prostate cancer were identified. Tomato sauce intake was 
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evaluated with the use of three food-frequency questionnaires that were administered at 
the beginning of the study and at 4-year intervals thereafter. In that study, consuming one 
or more than one serving of tomato sauce per week was associated with a statistically 
significant decreased incidence of prostate cancer (relative risk [RR] = 0.80, 95% 
confidence interval [CI] = 0.70 to 0.91 and 0.77, 95% CI = 0.66 to 0.90, respectively). 
Mills et al. 7 followed a cohort of 14,000 male Seventh-Day Adventists for 6 years, 
during which time 180 cases of prostate cancer were identified. In that study, consuming 
tomatoes one to four times per week or more than five times per week was associated 
with a statistically significant decreased incidence of prostate cancer (RR = 0.62, 95% CI 
= 0.40 to 0.96, and RR = 0.60, 95% CI = 0.37 to 0.97, respectively). 
A nested case-control study from the Health Professionals Follow-Up Study 
cohort further examined the association between plasma carotenoids and prostate cancer 
risk 8. By matching 450 cases with 450 controls, it was determined that there was a 
significant inverse relation between a higher concentration of serum lycopene and a lower 
risk of prostate cancer. This finding was restricted to older men and those without a 
family history of prostate cancer.  This epidemiological evidence supports the 
relationship between tomato product consumption and reduced risk for developing 
prostate cancer. 
Tomato consumption and cardiovascular disease (CVD).  Increased plasma 
lycopene levels have been associated with reductions in CVD risk and have also been 
reported to improve biomarkers associated with CVD.  For example, a study by Sesso et 
al. (2003) of 38,445 women found that higher levels of tomato-based product intake were 
associated with a reduced risk of cardiovascular disease (RR = 0.71, Ptrend= 0.029) and 
! 4 
myocardial infarction (RR = 0.43, Ptrend = 0.033) between the highest and lowest quintiles 
of intake 9. A separate study in Finnish men (n = 1,028) found an inverse association 
between serum lycopene concentrations and common carotid artery intima-media 
thickness, a measure of early atherosclerosis 10. In addition, a study using a subset of data 
(n = 4,557) from the third National Health and Nutrition Survey (NHANES III) observed 
decreased serum levels of carotenoids (including lycopene) in individuals with higher 
levels of C-reactive protein, a marker of inflammation 11. 
Some clinical trials have also supported a relationship between tomato 
consumption and reduced CVD risk factors. In a study by Hadley et al. (2003) 12, healthy 
individuals received one of three tomato treatments for 15 days (condensed tomato soup, 
ready- to-serve tomato soup, or V8® vegetable juice). Blood samples were taken at 
baseline and after treatment, and the low-density lipoprotein (LDL) plus very-low-density 
lipoprotein (VLDL) fraction was exposed ex vivo to oxidative stress. The lipoprotein 
oxidation lag period, a measure of protection against oxidative stress, was significantly 
increased in all three treatment groups. A separate clinical trial treated 24 subjects with 
either fresh tomato, tomato juice, or a lycopene drink (all delivering 40 mg lycopene/day) 
for six weeks 13. This study found that triglyceride levels and LDL cholesterol were 
decreased, and high-density lipoprotein (HDL) cholesterol increased in subjects who 
consumed fresh tomato and tomato juice. These epidemiological and clinical studies 
support the relation between tomato product consumption and reduced risk for CVD. 
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Tomato carotenoids: phytoene, phytofluene, and lycopene 
Carotenoid biosynthesis in tomato fruits 14.  In tomatoes, carotenoids are 
synthesized within the plastids by enzymes that are nuclear encoded.  Like all other 
isoprenoids, carotenoids are built from the 5-carbon compound isopentenyl diphosphate 
(IPP). In plastids, IPP is produced via in the ‘DOXP pathway’ from pyruvate and 
glyceraldehyde-3-phosphate (Figure 1.1). The first enzyme in this pathway is 1-
deoxyxylulose 5-phosphate (DOXP) synthase (DXS), and then the sequential addition of 
three IPP molecules to dimethylallyl diphosphate, which is catalyzed by a single enzyme, 
geranylgeranyl diphosphate (GGPP) synthase (GGPS), produces the 20-carbon molecule 
GGPP. 
The first committed step in the carotenoid pathway is the condensation of two 
GGPP molecules to produce 15-cis phytoene, which is catalyzed by a membrane-
associated enzyme, phytoene synthase (PSY). PSY is a rate-limiting enzyme of carotenoid 
biosynthesis in ripening tomato fruits and this rate-limiting feature makes PSY suitable to 
be a key regulator of carotenogenesis 15. Subsquently, two structurally and functionally 
similar enzymes, PDS and !-carotene desaturase (ZDS), convert phytoene to lycopene via 
!-carotene. These FAD-containing enzymes each catalyze two symmetric 
dehydrogenation reactions that require plastoquinone and a plastid terminal oxidase as 
electron acceptors. 
At the ‘breaker’ stage of ripening, the tomato color changes from green to orange 
because of the accumulation of lycopene, which takes place following increased synthesis 
of carotenoid enzymes. The mRNA levels for the enzymes PSY and PDS increase 10–20-
fold at the breaker stage of ripening 16. At the same time, the mRNAs of both lycopene 
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cyclases that produce carotenes, Lcy-b (CrtL-b) and Lcy-e (CrtL-e), disappear 17. It has 
been established that the increase in PSY and PDS expression during the breaker stage is 
controlled by transcriptional regulation 18. 
Carotenoids in fresh tomatoes and tomato products. In fresh tomatoes and 
tomato products, lycopene is the most abundant carotenoid, followed by phytoene, 
phytofluene and the provitamin A carotenoid, "-carotene (Table 1.1) according to the 
USDA National Nutrient Database. Other sources of lycopene include fresh watermelon 
(45.3 µg/g) and pink grapefruit (14.2 µg/g), but in the United States, 85% of lycopene 
exposure comes from tomato sources, like canned tomato sauces (139.8 µg/g). As the 
moisture content drops in the processed tomato products, the relative concentration of 
tomato carotenoids increases.  Many studies have looked at the stability, isomerization 
and degradation characteristics of lycopene during thermal processing 19. Overall, 
lycopene and its isoforms are stable under commercial processing conditions. 
 
Liberation, absorption, distribution, metabolism and excretion (LADME) of tomato 
carotenoids 
Carotenoids are not biosynthesized in the human body, and they have to be 
provided via oral consumption. Due to the nature of their hydrocarbon structures, 
carotenoids are highly lipophilic and absorbed/transported in a similar fashion to other 
dietary lipids, such as cholesterol and triacylglycerol. Many absorption studies have been 
done in humans and the pharmacokinetics of lycopene has been reported. The distribution 
patterns of tomato carotenoids were also observed in some human tissues and animal 
models. However, to date, only a little is known about the metabolism and the excretion 
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of tomato carotenoids. The current knowledge gap lies in the metabolism and excretion of 
absorbed and stored tomato carotenoids, the elucidation of which requires isotopically 
labeled carotenoids.  The current knowledge of tomato carotenoid LADME is 
summarized as below; most of our knowledge is derived from studies of beta-carotene or 
lycopene and very little is known about phytoene and phytofluene 20. 
Liberation. Carotenoids can be partially released from the food matrix by 
chewing and the action of stomach acids and digestive enzymes, and the efficiency of this 
process is greatly impacted by the food matrix itself. Thermal processing has been found 
to increase all-trans lycopene absorption by 3.8-fold, comparing the ingestion of tomato 
paste with that of fresh tomato 21. Dietary lipids have also been found to improve 
lycopene bioavailability in humans, as when tomato juice is warmed and consumed with 
supplemental lipids 22, or when salad is consumed with full-fat dressings 23.  
Absorption. As a result of the action of bile salts and pancreatic lipases, 
carotenoid-containing lipid droplets enter the duodenum and form micelles. Based on an 
in vitro beta-carotene study, it is generally believed that lycopene is also solubilized 
along with dietary triglycerides in the hydrophobic core of the micelles 24. However, the 
transfer of lycopene from the food matrix to micelles is less efficient than beta-carotene 
transfer 25. The mixed micelle then enters the unstirred water layer of the microvillus cell 
membrane of the enterocyte, where micelles can diffuse into the membrane and release 
fat and carotenoids into the cytosol of the cell 26. Recently, the Scavenger Receptor class 
B type I protein (SR-BI) was found to aid lycopene transport across the intestinal walls in 
SR-BI over-expressed transgenic mice, but blocking SR-BI in Caco-2 cells by inhibitors 
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only partially affected lycopene uptake 27,28, which indicates the potential that passive 
diffusion or other transporters are also responsible for lycopene uptake by enterocytes. 
It has been known that the newly absorbed lycopene can be found in 
chylomicrons in human serum 29, and therefore the carotenoids are very likely to be 
packed into chylomicrons in the Golgi apparatus of the enterocytes. However, how 
carotenoids are transported into the Golgi apparatus is not yet clear. Lycopene with 
different isoforms are absorbed differently. Lycopene cis-isomers have been found to be 
preferably absorbed in humans 30, ferrets 31 and Caco-2 cells 32. In addition, absorbed all-
trans lycopene has been found to be isomerized within the Caco-2 cells 33, which further 
increases the amount of cis-lycopene packed in chylomicrons and potentially results in 
the difference of isomer patterns when comparing food sources (mainly all-trans isomer) 
and mammalian tissues (mainly cis-isomers). When carotenoids are taken up by the 
enterocytes but not incorporated into chylomicrons, they are sloughed off during 
enterocyte turnover and enter the lumen of the gastrointestinal tract. 
Distribution. Carotenoids are distributed via lipoproteins, initiated with the 
secretion of chylomicrons by enterocytes. Through the action of lipoprotein lipase on 
chylomicrons, lycopene and other carotenoids have the potential to be taken up passively 
by various tissues, including adrenals, kidney, adipose, spleen, lung, and reproductive 
organs before clearance of chylomicron remnants by the liver via the chylomicron 
receptor. Carotenoids can accumulate in the liver or can be repackaged into VLDL and 
sent back into the blood. Uptake of carotenoids into tissues from VLDL and LDL is 
thought to occur via the LDL receptor, and the tissues with the highest concentrations of 
carotenoids (liver, adrenal, testes) tend to have high LDL receptor activity 34. The relative 
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distributions of tomato carotenoids in human plasma lipoproteins are summarized in the 
Table 1.2, and the concentrations of tomato carotenoids in human tissues are summarized 
in the Table 1.3. Lycopene is the predominant carotenoid in human liver, prostate, 
adipose tissue, adrenals and testes. 
Metabolism and Excretion. Very little is known about mammalian metabolism 
or degradation of phytoene, phytofluene, or even lycopene. Auto-oxidation 35, beta-
oxidation 36 and enzymatic cleavage 37 have been proposed to degrade lycopene in vivo. 
Only a few metabolites, such as 5,6-dihydroxy-5,6-dihydrolycopene, have been detected 
in human plasma. It was proposed that lycopene may undergo in vivo oxidation to form 
epoxides which then may be converted to the polar 5,6-dihydoxy-5,6-dihydrolycopene 
through metabolic reduction 38. One human study observed 14CO2 in breath and 14C-
enriched polar metabolites in urine from a single dose of 14C-lycopene, after which beta-
oxidation was proposed 36. Our laboratory has also observed a number of other polar 
products that have yet to be identified, as well as identified apo-8’-lycopenal and 
potentially apo-12’-lycopenal as metabolites of lycopene in the liver of F344 rats fed 
lycopene 39. Similar work has also been done in the ferret lung, from which apo-10’-
lycopenol was reported as an enzymatically cleaved product 37. Enzymatic cleavage will 
be further discussed in detail later. 
Pharmacokinetics. Both non-compartmental and compartmental models have 
been used to evaluate the pharmacokinetics of lycopene in human 40,41. A non-
compartmental, single-dose Phase I pharmacokinetic study in healthy adult male subjects 
found the mean time (tmax) to reach maximum total serum lycopene concentration (Cmax) 
ranged from 15.6 to 32.6 h. The Cmax for total lycopene ranged between 0.075-0.210 µM 
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41. Mean AUC0-96 and elimination half-life for total lycopene ranged from 3.986-12.201 
µmol h/L) and 28.1-61.6 h. Interestingly, the changes observed in lycopene exposure 
parameters were not proportional to increments in dose, with larger increases observed at 
the lowest end of the dosing range (10-30 mg). Chylomicron lycopene was measured 
during the first 12 h with the differences observed among the dosing groups not reaching 
statistical significance. These findings may reflect a process of absorption that is 
saturable at very low dosing levels or may be explained by the large inter-individual 
variability in attained lycopene concentrations that were observed within each dosing 
group. 
Another pharmacokinetics study with a compartmental model included seven 
compartments in the study: gastrointestinal tract, enterocytes, chylomicrons, plasma 
lipoproteins, fast-turnover liver, slow-turnover tissues, and a delay compartment before 
the enterocytes (Figure 1.2) 40. The investigators found that the percent absorption (33.9 
+/- 8.1%) at the 10 mg dose, equal to 0.83 oz. of Hunt’s tomato paste in 0.8 US teaspoon 
of olive oil, was significantly greater than at the higher doses. However, the amount of 
lycopene absorbed (mean 4.69 +/- 0.55 mg) was similar between doses, also suggesting a 
possible saturation of absorptive mechanisms. Independent of dose (10, 30, 60, 90, or 120 
mg), 80% of the subjects absorbed less than 6 mg of lycopene. They also found that in 
most subjects the concentration of serum lycopene peaked twice following dosing, with 
one at the 6.7 h and another at the 28.2 h. The predicted flow rates and fractional transfer 
coefficients (FTCs) for lycopene between compartments were also listed in the Figure 
1.2, indicating lipoproteins play an important role in carotenoid transportation. 
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Mammalian carotenoid cleavage enzymes: CMO-I and CMO-II 
Discovery of CMO-I. In 1965, Goodman & Huang 42 and Olson & Hayaishi 43 
characterized an enzymatic activity in cell-free homogenates from rat small intestine that 
converted ", "-carotene into retinaldehyde. Wyss and colleagues then cloned the first 
vertebrate ", "-carotene-15,15’- monooxygenase (CMO-I) from chicken 44,45. 
Subsequently, CMO-I genes from mice, rats and humans were identified, and the 
recombinant proteins were biochemically characterized 46-49. Recombinant human CMO-I 
catalyzes the cleavage of provitaminA carotenoid substrates with at least one non-
substituted "-ionone ring, such as ", "-carotene, #-carotene, and "-cryptoxanthin, but fails 
to cleave non-provitamin A carotenoids such as lycopene or zeaxanthin 48. 
Distribution of CMO-I. According to Entrez Gene (NCBI), the human CMO-I 
gene maps on chromosome 16 at 16q21-q23 and the protein localizes to the cytoplasm of 
human cells 48. Immunohistology has shown that CMO-I is expressed in epithelial cells in 
various human tissues, including the mucosal and glandular cells of the stomach, small 
intestine and colon; parenchymal cells in the liver; cells comprising the exocrine glands 
in the pancreas; glandular cells in the prostate, endometrium, and mammary tissue; 
kidney tubular cells; and keratinocytes of skin squamous epithelium. Additionally, 
steroidogenic cells in testis, ovary and the adrenal gland, as well as skeletal muscle cells, 
express CMO-I (Table 1.4) 50. Moreover, CMO-I is abundantly expressed in the retinal 
pigmented epithelium of the eyes 51,52. Interestingly, murine CMO-I is expressed in 
hepatic stellate cells, instead of hepatocytes in the mouse liver 53. 
Characteristics of CMO-I. Km values for "-carotene are estimated to be in the 
range of 7.1 $M, and the Vmax value for "-carotene at 10.4 nmol/mg/min 48. CMO-I 
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exhibits a slightly alkaline pH-optimum, and its enzymatic activity is sensitive to 
chelating agents such as o-phenanthroline and #, #’- bipyridyl, indicating a dependency 
on ferrous iron 48,49. The presence of ferrous iron in recombinant CMO-I was then 
confirmed by inductively coupled plasma atomic emission spectrometry 54. In murine 
CMO-I, binding of this cofactor involves four conserved histidine residues (His172, 
His237, His308, and His514) and a conserved glutamine (Glu405) that are all essential 
for enzymatic activity 54. In addition, the Lys residue at position 108 of human CMO-I 
was found critical for the affinity with substrates with ionone rings at both ends, such as 
#-carotene, "-carotene, and "-cryptoxanthin 55. 
Tomato carotenoids and CMO-I.  In lycopene-fed rats, CMO-I mRNA 
expression was found to be lower in the kidney and adrenal tissues compared to control 
fed rats 56. In CMO-I knockout mice fed 150 mg/kg of lycopene, our laboratory found 
significant decreases in hepatic, spleen, and thymus lycopene concentrations and 
significant increases in prostate, seminal vesicles, testes, and brain lycopene 
concentrations compared with wild type mice. Furthermore, in the serum and all tissues 
analyzed, excluding the testes, there was a significant increase in the percent lycopene cis 
isomers in CMO-I knockout mice 57. These findings indicate that there is a two-way 
interaction between dietary lycopene and CMO-I, although lycopene is not a substrate of 
CMO-I 48. In addition, the mRNA expression of murine CMO-II was found elevated by 
2-fold in CMO-I knockout mouse liver 53, which indicates that the enzyme CMO-II might 
partially compensate the function of CMO-I. 
Discovery of CMO-II. An asymmetric enzymatic cleavage of carotenoids was 
proposed in 1991 58, and the carotenoid-oxygenase, carotene- 9’, 10’-monooxygenase 
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(CMO-II, BCO2 or BCDO2), was then cloned from mouse, human, zebra fish 59, rats 56 
and ferrets 37. Recombinant mouse and ferret CMO-II were biochemically characterized 
37,59-61. To date, our knowledge of CMO-II is established solely based on the mouse and 
ferret models due to the lack of human CMO-II data. 
Distribution of CMO-II. In humans, CMO-II gene maps on chromosome 11 at 
11q22.3-q23.1, the Homo sapiens complex locus SDHD, which encodes 4 non-
overlapping genes: 1) succinate dehydrogenase complex, subunit D, integral membrane 
protein (SDHD), and 2) testis expressed 12 (TEX12), and 3) beta-carotene oxygenase 2 
(BCO2), and 4) ribosomal protein S12 pseudogene 21 (RPS12P21) (AceView, NCBI). 
There is no evidence demonstrating the intracellular location of human CMO-II, but the 
immunocytochemistry showed that human CMO-II is expressed in epithelial cells of 
small intestine and stomach mucosa, parenchymal cells of liver (hepatocytes), Leydig and 
Sertoli cells of testis, kidney tubules, adrenal gland, exocrine pancreas, and retinal 
pigmented epithelium and ciliary body of the eye. CMO-II, but not CMO-I, was detected 
in cardiac and skeletal muscle cells, prostate and endometrial connective tissue, and 
endocrine pancreas (Table 1.4) 50.  
Mouse CMO-II maps on chromosome 9 at 9B (Entrez Gene, NCBI), and when 
mouse CMO-II is expressed in monkey kidney cells COS-7, it is found to locate in 
mitochondria by immunostaining and confocal imaging 60. The mRNA expression of 
mouse CMO-II can be detected in mouse small intestine, brain, liver, kidney, and testis 
59. However, when ferret CMO-II is expressed in monkey kidney cells COS-1, it was 
found to locate in cytoplasm. CMO-II is also expressed in a wide variety of ferret tissues, 
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including liver, testis, heart, spleen, lung, intestine, colon, stomach, kidney, bladder and 
prostate 37.  
Characteristics of CMO-II. Expression of mouse CMO-II in a "-carotene-
accumulating E. coli strain revealed that it catalyzes the formation of "-10’-carotenal and 
"-ionone 59. When mouse CMO-II was expressed in a lycopene-accumulating E. coli 
strain, the pink color was bleached, which indicates potential cleavage of lycopene by 
mouse CMO-II 59. Furthermore, the recombinant mouse CMO-II was found to cleave 
xanthophylls like lutein and zeaxanthin in vitro 60. Similar results were also obtained with 
recombinant ferret CMO-II 37,61, but ferret CMO-II was found to preferably cleave 5-cis 
and 13-cis-isomers of lycopene instead of all-trans-lycopene 37. These findings suggested 
that CMO-II has broad substrate specificity. 
Enzymatic kinetics of CMO-II were only reported from the recombinant ferret 
CMO-II studies 37,61. The optimum reaction pH occurs between pH 8.0 to 8.5, and the 
Km values for "-carotene, lutein, zeaxanthin, and "-cryptoxanthin are 3.5, 51.69, 49.6 
and 80.8 $M, respectively. The Vmax value for "-carotene is 32.2 pmol of apo-10’-
carotenal/mg/h, and the values for lutein, zeaxanthin and "-cryptoxanthin are 48.4, 69.87 
and 34.26 pmol of 3-hydroxyl-"-apo-10’-carotenal/mg/min. Km and Vmax values for 
lycopene were not reported, but were estimated to be lower than that for "-carotene. Iron 
was found to be an essential cofactor for the "-carotene reaction, whereas iron and NAD+ 
were both critical for lutein, zeaxanthin, "-cryptoxanthin and lycopene reactions. 
Biological impact of CMO-II. Chicken, cow, sheep and knockout mouse models 
provided some insights regarding the role of CMO-II 62-66. In domestic chickens, the 
yellow skin color is determined by cis-acting and tissue-specific regulatory mutation(s) 
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that inhibit expression of CMO-II in skin. In contrast to skin, CMO-II is normally 
expressed in other organs such as the liver 62. This observation in chickens indicates that 
CMO-II can metabolize carotenoids in a tissue-specific manner. Moreover, the "-carotene 
of cow milk was significantly increased by a mutation that abolished CMO-II function, 
with serum "-carotene concentrations also higher in CMO-II deficient cows 63. Sheep 
carrying mutated CMO-II were strongly associated with the yellow fat phenotype, which 
contains mainly lutein and flavoxanthin 65. CMO-II knockout mice also accumulated 
large amounts of supplemented lutein, zeaxanthin or lycopene in serum and tissues 60,66, 
which further indicates the role of CMO-II in carotenoid degradation in mammals. 
However, the concentrations of phytoene and phytofluene did not increase in serum or 
other organs in the tomato powder-fed CMO-II knockout mice, which indicates that 
phytoene and phytofluene might not be substrates for the CMO-II enzyme, or did not 
accumulate in high enough concentrations to induce metabolic cleavage 66. Recently it 
was found that two single nucleotide polymorphisms (SNPs) in the human CMO-II gene 
intron 2 are associated with altered interleukin-18 levels in human plasma, but the 
mechanism for this is not yet known 67. 
 
Applications of isotopically labeled carotenoids 
Quantitative mass spectrometry. In biological samples, there are a variety of 
competing effects in the ionization source that compete with the carotenoids for 
ionization. These may either enhance or suppress the signal and would result in 
artificially reduced or elevated quantitative measurements, respectively. Some of these 
matrix effects are due to the presence of ionic species, buffer ions, and high 
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concentrations of non-target analytes. Use of a stable-isotope internal standard can 
correct such competing ionization processes 68. A known concentration of stable-isotope 
internal standard can be spiked into the sample matrix before analysis. The only thing 
that differentiates the stable-isotope internal standard from the target carotenoid is a small 
mass difference due to the degree of labeling. Generally, 13C labeling is preferred as there 
is always the possibility that hydrogen exchange with deuterium can occur in deuterated 
internal standards. 
LADME studies. As it is difficult to completely deplete carotenoids from 
humans, stable isotope labeled carotenoid tracers will allow a single carotenoid dose to be 
followed within pre-existing, endogenous pools. Previously, labeled lutein and "-carotene 
have been utilized to provide information regarding 1) the fraction of the ingested amount 
that is absorbed (bioavailability), 2) the fraction of that which is converted to vitamin A 
in the body (bioconversion), 3) the estimated body stores of vitamin A, and 4) interaction 
between retinal and rhodopsin 69-74. Additionally, deuterium-labeled lycopene obtained 
either by chemical synthesis or from intrinsically labeled tomatoes grown hydroponically 
were used to determine the relative bioavailability of lycopene from steamed and pureed 
tomato versus synthetic lycopene in oil. The results showed that the synthetic lycopene in 
oil was 3 times more bioavailable than pureed tomato 75. Two studies from our laboratory 
focused on the absorption and distribution of synthetic 14C-lycopene in F344 rats 76,77, 
and one recently published study with a low dose of 14C-lycopene in human, also 
provided information regarding the metabolism of lycopene 36. To date, no tracer studies 
utilizing isotope labeled phytoene or phytofluene have been conducted, either in animals 
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or humans and therefore very little is known regarding the ADME of phytoene and 
phytofluene. 
 
Carotenoid production systems 
Carotenoids are produced in a large quantity mainly because of their coloring 
properties. They are used for the direct coloring of foodstuffs as well as for enhanced 
pigmentation of animal products by administration in the feed of shrimp, salmon or egg-
laying hens, for example. According to a report by the Business Communications Co. 
Inc. (BCC, Norwalk, CT), the total global carotenoid market in 2007 was $766 million 
USD. Beta-carotene accounted for $247 million, and followed by astaxanthin (~$220 
million), canthaxanthin (~$110 million), annatto (~$65 million) and others (~$120 
million), including lutein, zeaxanthin, lycopene, apo-carotenals and apo-carotenal-esters. 
Methodologies including chemical synthesis and production by microalgae, yeast, 
bacteria and tomato cells have been developed to produce carotenoids. 
Total synthesis. Currently the majority of carotenoids are chemically synthesized 
by two chemical companies, BASF (Ludwigshafen, Germany) and DSM (Basel, 
Switzerland). Two fundamentally different strategies have been developed for the 
industrial synthesis of carotenoids. In one, the synthesis proceeds via vitamin A. This can 
be elongated to give the apocarotenoids or converted into beta-carotene, which is 
oxidized to canthaxanthin and astaxanthin. The alternative approach is to prepare a 
specific trimethylcyclohexanone end group synthon for each carotenoid. The typical 
reactions utilized by DSM are the Grignard reaction and the enol ether condensation, and 
BASF uses the ethynylation and the Wittig reaction. Microcrystalline dispersion in fat or 
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hydrophilic colloids has been developed to transform the pure, crystalline, lipophilic 
compound into formulations that are suitable for application 78. 
Microalgae. The marine algae Dunaliella salina is employed for manufacturing 
of beta-carotene, while the production of astaxanthin is done with the fresh water algae 
Haematococcus pluvialis, which can accumulate up to 4% of astaxanthin based on its dry 
weight. Several concepts for the phototrophic mass culture of algae have been proposed 
and compared to each other 79-81. Open systems including ponds or raceway tracks 
compete with closed systems like glass tubes or flat panel reactors. Today Dunaliella is 
grown in open pond systems by Cognis (now part of BASF) and is also produced by 
Proalgen Biotech Ltd., Parry Nutraceuticals and ABL Biotechnologies in India, whereas 
Haematococcus is produced either in closed or in open reactors, e.g., by Algatech, 
Cyanotech or Parry Nutraceuticals. 
Fungi. Blakeslea trispora is currently the best fungal strain employed for the 
production of beta-carotene, commercially utilized by DSM. B. trispora produces up to 
3% carotene per cell dry weight in an optimized industrial production process. Other 
fungal sources rich in beta-carotene are Mucor circinelloides and Phycomyces 
blakesleeanus 82. Besides beta-carotene, B. trispora is also employed for the production 
of natural lycopene, commercialized by Vitatene. For the production of astaxanthin, the 
yeast Xanthophyllomyces dendrorhous, formerly known as Phaffia rhodozyma, is 
applied. Although the final concentration of astaxanthin is below 1% per cell dry weight, 
this process has been commercialized by the Archer Daniels Midland Company (ADM). 
Tomato cell culture.  Tomato cell suspension cultures of tomato (Lycopersicon 
esculentum cv. VFNT cherry) has been developed for laboratory scale production of 
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phytoene, phytofluene and lycopene 83. When the cells were treated with the herbicide 
norflurazon, phytoene and phytofluene accumulated in their natural isomeric forms (15-
cis-phytoene and two cis-phytofluene isomers). Maximum yields of both phytoene and 
phytofluene were achieved after 7 days of treatment with 0.03 mg norflurazon / 40 mL 
fresh medium, provided in 0.07% solvent carrier 83. This system was further optimized by 
treating cells with two bleaching herbicides, 2-(4-chlorophenyl-thio)triethylamine 
(CPTA) and norflurazon, and treatment with both herbicides resulted in optimal 
production of all three carotenoids 84. Among selected tomato cell culture lines, hp-1 
suspensions yielded highly enriched 13C-lycopene with 45% of lycopene in the M+40 
form and 88% in the M+35 to M+40 isotopomer range when grown with [U]-13C-glucose 
and treated with CPTA 85. 
Bioengineered Escherichia coli. A number of carotenogenic genes (Figure 1.3) 
have been cloned from microorganisms. For example, the purple non-sulphur anaerobic 
photosynthetic bacteria Rhodobacter capsulatus 86, the yellow non-photosynthetic 
bacteria Erwinia herbicola 87 or Erwinia uredovora 88, and the cyanobacteria 
Synechococcus sp. 89 have all been used. These genes were introduced and expressed in 
E. coli and resulted in the recombinant biosynthesis of various acyclic, cyclic, and 
oxygenated carotenoids (Table 1.5) 90-93. DNA shuffling and combination of different 
carotenoid biosynthetic genes have resulted in the production of novel carotenoids 94,95. 
Additionally, metabolic engineers have used this system to increase the carotenoid 
production tremendously by introducing the mevalonate pathway 96, increasing 
precursors 97, or knocking out unnecessary genes 98-100. Since E. coli can utilize glucose 
! 20 
as its sole carbon source, the bioengineered E. coli system could be a good production 
system for isotopically labeled carotenoids from labeled glucose. 
 
Aims of Dissertation 
Tomatoes and tomato products are consumed globally and tomato carotenoids are 
believed to potentially decrease the risks of CVD and prostate cancer. However, the 
distribution, metabolism and excretion of tomato carotenoids, once consumed, are still 
unclear. One major challenge of this type of research lies in the supply of research tool: 
isotopically labeled tracers. Although many industrial production methods have been 
commercialized, isotopically labeled carotenoids are not being produced for research 
purposes. Therefore, the specific aims of this research are: 
Aim 1: To optimize the extraction efficiency of the tomato carotenoid lycopene 
from a tomato cell suspension culture system. 
Aim 2: To establish a laboratory-scale 13C-labeled carotenoid production system 
using bioengineered E. coli cultured with 13C-glucose as the only carbon source. 
Aim 3: To express the human CMO-II enzyme in E. coli and examine its 
biochemical functions towards the cleavage of carotenoids. 
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Table 1.1 Carotenoid content of fresh tomatoes and tomato products 
 Tomato products 
Carotenoid Raw tomatoes Catsup 
Tomato 
juice 
Tomato 
sauce 
Tomato 
paste 
   µg/100 g   
Phytoene2 1860 3390 1900 2950 8360 
Phytofluene2 820 1540 830 1270 3630 
Lycopene1 2573 16709 9037 13979 28764 
#-carotene1 101 0 0 0 29 
"-carotene1 449 560 270 259 901 
"-cryptoxanthin1 0 0 0 3 0 
Lutein + zeaxanthin1 123 0 60 23 0 
1 USDA Nutrient Data Bank Numbers (NDB No.): raw tomatoes, 11529; catsup, 11935; 
tomato juice, 11540; tomato sauce (11549); tomato paste, 11887. 
2 Adapted from Tonucci, L. et al. 101 
 
 
 
 
Table 1.2 Relative distributions of tomato carotenoids in human plasma lipoproteins 102 
 VLDL LDL HDL 
  %  
Phytoene 17 76 5 
Phytofluene 22 65 13 
Lycopene 7 76 17 
 
 
 
 
Table 1.3 Tomato carotenoids in human tissues 38 
 Serum Liver Lung Breast Prostate Fat Adrenal Testis 
 nmol/L ng/g ng/g ng/g ng/g nmol/g nmol/g nmol/g 
Phytoene 35-61 168 1275 69 45 NR NR NR 
Phytofluene 124-255 261 195 416 201 NR NR NR 
Lycopene 606-735 352 300 234 374 0-510 0.19-5.6 0.41-9.38 
Ref 102 38,103,104 103 38 38 38 38 104 
 
NR: not reported 
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Table 1.4 Comparison of immunohistochemical detection of CMO-I 
(BCO1) and CMO-II (BCO2) in normal human tissues 50 
 
                              (Reproduced with permission, Copyright 2005 SAGE) 
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Table 1.5 Gene combinations of carotenoid biosynthesis and the resulting major 
carotenoid accumulated in E. coli 90. Subscripts indicate the organisms from which the 
carotenogenic genes have been cloned: EU Erwinia uredevora, EH Erwinia herbicola, SY 
Synechocystis sp., RC Rhodobacter capsulatus, RS Rhodobacter sphaeroides, CA 
Capsicum annuum, AA Agrobacterium aurantiacum, HP Haematococcus pluvialis, AN 
Anabaena, AL Alcaligenes sp., AT Arabidopsis thaliana, XD Xanthophyllomyces 
dendrorhous, SA Staphylococcus aureus, CG Corynebacterium glutamicum. 
 
 
 
(Reproduced with permission, Copyright 2005 Springer) 
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Figure 1.1 The carotenoid biosynthesis pathway in plants. Enzymes are named according 
to the designation of their genes 14. A, DPME; B, 4-diphospho-cytidyl-2C-methyl-D-
erythritol 2-phosphate; C, 2C-methyl-D- erythritol 2,4-cyclodiphosphate. AO, adldehyde 
oxidase; CrtR-b, "-ring hydroxylase, CrtR-e, &-ring hydroxylase; DMADP, dimethylallyl 
diphosphate; DOXP, 1-deoxy-D-xylulose 5-phosphate; ispF, 2C-methyl-D-erythritol 2,4-
cyclodiphosphate; MEP, 2-C-methyl-D- erythritol 4-phosphate. (Reproduced with 
permission, Copyright 2001 Elsevier) 
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Figure 1.2 A physiological pharmacokinetic model describing the disposition of 
lycopene in healthy men at five dose levels (10 mg, 30 mg, 60 mg, 90 mg, 120 mg) 40. 
Each compartment contains a kinetically distinct form of lycopene. Arrows represent the 
connectivity between compartments. The fractional transfer coefficients (FTCs), L(I,J), 
depicted in bold italics, are the kinetic constants derived by fitting the model to the 
experimental data. They refer to the rate at which lycopene is transferred from 
compartment J to compartment I per unit of time. The numbers alongside the arrows are 
the mean steady state flow rates (flow out = flow in) at all doses (µmol/day) between 
compartments, which are calculated by multiplying the steady state mass in the donor 
compartment by the FTCs from the donor to acceptor compartment. (Reproduced with 
permission, Copyright 2003 Lipid Research Inc.) 
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Figure. 1.3 Carotenoid biosynthesis pathways in microorganisms and plants. 
Biosynthesis pathways of C30 (A), C40 (B) and C50 (C) carotenoids in microorganisms 
and plants from which the enzymes have been cloned 90. Terminal products of 
biosynthesis routes are shown. Enzymes from plants, algae and cyanobacteria are given 
in parentheses. (A) crtM dehydrosqualene synthase, crtN dehydrosqualene desaturase. 
(B) crtE, al-3, gps GGPP synthase; crtB, al-2, psy phytoene synthase; crtI, al–1, crtP, pds 
phytoene desaturase; crtQ, zds !-carotene desaturase; crtY, crtL-b lycopene "-cyclase; 
crtL-e lycopene &-cyclase; crtZ, crtR-b "-carotene hydroxylase; crtW, crtO, bkt "-
carotene C(4) oxygenase; crtX zeaxanthin glucosylase; zep zeaxanthin epoxidase; vep 
violaxanthin deepoxidase; ccs capsanthin/capsorubin synthase; crtU "-carotene 
desaturase; crtC hydroxyneurosporene synthase; crtD methoxyneurosporene desaturase; 
crtF hydroxyneurosporene-O-methyltransferase; crtA spheroidene monooxygenase. (C) 
crtEb Lycopene elongase, crtYe/Yf heterodimeric decaprenoxanthin synthase. 
(Reproduced with permission, Copyright 2005 Springer.) 
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CHAPTER 2: 
Optimization of Lycopene Extraction from Tomato Cell Suspension Culture 
by Response Surface Methodology1 2 
 
Abstract 
Radioisotope-labeled lycopene is an important tool for biomedical research but 
currently is not commercially available. A tomato cell suspension culture system for the 
production of radioisotope-labeled lycopene was previously developed in our laboratory. 
In the current study, the goal was to optimize the lycopene extraction efficiency from 
tomato cell cultures for preparatory HPLC separation. We employed response surface 
methodology (RSM) which combines fractional factorial design and a second-degree 
polynomial model. Tomato cells were homogenized with ethanol, saponified by KOH, 
extracted with hexane, and the lycopene content was analyzed by HPLC-PDA. We varied 
five factors at five levels: ethanol volume (1.33-4 mL/g); homogenization period (0-40 
s/g); saturated KOH solution volume (0-0.67 mL/g); hexane volume (1.67-3 mL/g); and 
vortex period (5-25 s/g). Ridge analysis by SAS suggested that the optimal extraction 
procedure to extract 1 g of tomato cells was at 1.56 mL ethanol, 28 s homogenization, 
0.29 mL KOH, 2.49 mL hexane, and 17.5 s vortex. These optimal conditions predicted by 
RSM were confirmed to enhance lycopene yield from standardized tomato cell cultures 
by more than 3-fold. 
Introduction 
Increased consumption of tomato and tomato products has been significantly 
                                                
1 This chapter was the result of a collaboration of the following authors: Chi-Hua Lu, Nancy J. Engelmann, 
Mary Ann Lila, and John W. Erdman, Jr. 
2 Reproduced with permission from J. Agric. Food Chem., 56, 7710-7714. Copyright 2008 American 
Chemical Society. 
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associated with a reduced risk of prostate cancer in several epidemiological studies 1. 
Carotenoids are yellow, orange and red pigments present in fruits and vegetables which 
possess a wide range of proposed biological functions, including antioxidant, 
anticarcinogen, and immunoprotective properties. Lycopene, the most abundant tomato 
carotenoid, has been the primary focus of both in vitro and in vivo studies examining the 
relationship between increased intake of tomatoes and reduced risk of prostate cancer. 
Numerous epidemiological studies have shown that higher serum lycopene concentration 
is inversely related to prostate cancer risk 2-4. 
To study their modes of action, radiolabeled carotenoids are indispensable tools and 
are often used to trace the absorption, distribution, metabolism and elimination of the 
dietary compound of interest 5. There exists a keen interest in the influence of tomato 
carotenoids on the risk of prostate cancer 1,6,7; however, radiolabeled carotenoids like 
lycopene and its precursors are not commercially available. Therefore, a tomato cell 
suspension culture system was developed in our laboratory to biosynthesize and 
radiolabel tomato carotenoids for in vitro prostate cancer cell studies 8. In this system, 
14C-labeled sucrose was used as a carbon source and the herbicide norflurazon was added 
to the cell suspension culture to induce biosynthesis and maximize accumulation of 
carotenoids. These radiolabeled carotenoids were successfully produced, but the recovery 
of radiolabeled carotenoids did not meet our expectation. Multiple steps like cell 
destruction, lipid removal, and liquid-liquid partition could influence the yield during 
extraction process, and the interaction between these factors could be very complex. 
Therefore, a sophisticated statistical method is necessary for optimizing this extraction 
method. 
Response surface methodology (RSM) is a useful statistical technique which 
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combines fractional factorial design and a second-degree polynomial model to investigate 
complex processes, and it has been widely used in different fields. The original concept 
was developed by Box and Wilson 9 and the basic theoretical, fundamental, and 
biological applications were reviewed by Mead and Pike 10. Our goal was to optimize the 
lycopene extraction procedure by applying the response surface methodology, and to 
further maximize the radiolabeled carotenoid isolation from tomato cells for use in 
prostate cancer research. 
Materials and Methods 
Materials. Lycopene standard was a gift from DSM Nutritional Products 
(Kaiseraugst, Switzerland). HPLC solvents were purchased from Fisher Scientific (Fair 
Lawn, NJ). All reagents were of analytical grade. 
Tomato cell suspension culture. Tomato callus was induced from sepal explants of 
greenhouse-grown tomato plants, Lycopersicon esculentum cv. VFNT Cherry, on agar-
solidified medium as previously described 8. Briefly, the medium used for callus 
induction contained Murashige and Skoog basal salts, Nitsch's vitamins, myo-inositol 
(100 mg/L), and 3% sucrose, supplemented with plant growth regulators 2, 4-
dichlorophenoxyacetic acid (2 mg/L) and 6-benzylaminopurine (0.1 mg/L) and solidified 
with agar. Once friable callus was obtained, approximately 2.0 g of callus was transferred 
to 40 mL of liquid medium identical to callus induction media. 
Solution cultures were transferred to a carotenoid production media in 250 mL 
Erlenmeyer flasks containing the plant growth regulators indole-3-acetic acid (5 mg/L) 
and all-trans-zeatin (2 mg/L) and placed on a rotary shaker at 160 rpm. Cultures were 
continuously maintained on this media by regularly subculturing 4 mL packed cells and 8 
mL of spent media to fresh media every 2 weeks. For carotenogenesis induction, 2-(4-
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chlorophenylthio)triethylamine (CPTA) (0.075 g/L) was added on day one of the growth 
cycle. After a 2 week growth cycle, cells were harvested and separated from the growth 
media using Whatman no. 4 filter paper and gentle vacuum until no liquid was expressed 
for 30 s. Collected cells were mixed before sampling to minimize variation, stored under 
argon, and frozen at -80˚ C until extraction. Two batches of tomato cells were used in this 
study: the first batch was used for model construction, and the second batch was only 
used in the verification experiments. 
Lycopene extraction. The extraction method was modified from our original 
method which was developed and used for tomato cell extraction 8. Lycopene was 
extracted from tomato cells by placement of 3 g of cells and 4-12 mL of ethanol with 
0.1% butylated hydroxytoluene (BHT), into a 35 mL centrifuge tube. Samples were 
thoroughly mixed on a vortex at level 8 (Vortex, model G560; Scientific Industries, 
Bohemia, NY), homogenized at level 7 for 0-120 s (Homogenizer, Kinematica PCU1; 
Brinkmann, Westbury, NY), and then saponified by 0-2 mL of saturated KOH solution 
immersed in a 60˚ C water bath. Subsequently, 2 mL of deionized water and 5-9 mL of 
hexane were added, and samples were mixed at vortex level 8 for 15-75 s and then 
centrifuged for 10 min at 4˚ C (Centrifuge, model CR3i; Jouan, Winchester, VA). The 
hexane phase was removed and retained. The process of hexane addition, mixing, and 
centrifugation was repeated three times. Extracts were pooled and dried in a Speedvac 
evaporator (model 160; Savant, Farmingdale, NY), flushed with argon, and stored in a -
20˚ C freezer less than 24 hours prior to the HPLC-PDA analysis. The whole process was 
performed under yellow light. 
HPLC analysis. Lycopene was analyzed by a reverse-phase HPLC-PDA system. 
The system consisted of a Rainin Dynamics gradient pump (model SD-200; Varian, 
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Walnut Creek, CA), a Prostar pump (model 210; Varian), a C30 column (4.6!3!150 mm, 
YMC, Wilmington, NC) with a pre-column, a photodiode array detector (model 2996; 
Waters, Milford, MA), and Millennium32 software (Waters). Solvent A consisted of 83% 
of methanol, 15% of methyl-tert-butyl ether (MTBE), and 2% of 1.5% ammonium acetate 
aqueous solution. Solvent B consisted of 8% of methanol, 90% of MTBE, and 2% of 
1.5% ammonium acetate aqueous solution. The gradient procedure at a flow rate of 1 
mL/min was as follows: 10% B hold for 5 min, 12-min linear gradient to 65% B, 12-min 
linear gradient to 95% B, 5-min hold at 95% B, 2-min linear gradient to 10% B, and 2-
min hold at 10% B for a final time of 38 min. The column was maintained at room 
temperature, and the detector was set at 472 nm. All analyses were performed in duplicate 
and the quantification of lycopene was carried out with analytical standard (DSM, !max＝
472 nm, A1cm1%＝3450 in hexane). 
Experimental design. A central composite design 11 was used to investigate the 
effects of five independent variables, ethanol volume (X1), homogenization duration 
(X2), KOH volume (X3), hexane volume (X4), and vortex duration (X5) on the yield of 
lycopene (Y). The independent variables were coded at five levels (-2, -1, 0, 1, and 2), 
and the complete design consisted of 32 experimental points including six replications of 
the center points (all variables were coded as zero) (Table 2.1). The 32 sets of 
experiments were performed in a random order. 
Statistical analysis. The experimental data were fitted to the following second-order 
polynomial equation by statistical analysis system (SAS Institute, Cary, NC) through the 
response surface regression (RSREG) procedure. 
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Y is the response (lycopene content, nmol/g); A0, Ai, Aii, and Aij are constant coefficients; 
and Xi is the uncoded independent variable. The model was predicted through regression 
analysis and analysis of variance (ANOVA). Response surfaces were developed using 
fitted polynomial equations in SAS. The optimal extraction conditions for maximized 
lycopene yield was pre-established by ridge analysis 11 (RIDGE MAX procedure in 
SAS). 
Verification of method improvement. The degree of method improvement was 
determined by comparing the lycopene yield of the optimal extraction conditions as 
predicted by SAS (RSM Method), and the central-point extraction conditions (Central-
Point Method), in which all variables were coded as zero (Table 2.1). We also compared 
these two methods with our original method (Original Method), which was previously 
developed and used for tomato cell extraction 8. Fisher's least-significant-difference test 
was applied for the comparison of these three methods. 
 
Results and Discussion 
Model Fitting.  
Lycopene yields of 32 sets of variable combinations were obtained and analyzed 
(Table 2.2) by HPLC analysis, and fitted into a second-order polynomial equation by an 
RSREG procedure. Estimated values of regression coefficients were also obtained (Table 
2.3), and the regression model was predicted as follows: 
Y＝63.85－17.61 X1＋0.69 X2＋74.52 X3－36.09 X4－0.71 X5＋5.037X12－0.009 X22
－27.409 X32＋5.523 X42－0.006 X52－0.309 X1X2＋0.563 X1X3－0.844 X1X4－0.356 
X1X5－0.563 X2X3＋0.394 X2X4＋0.006 X2X5－19.125 X3X4－0.375 X3X5＋0.863 
X4X5 
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The predicted values of lycopene yield were calculated by using the predicted 
regression model and compared with experimental values (Table 2.2). The value for the 
coefficient of determination (R2) was 0.88 which indicates adequacy of the applied 
model. The statistical analysis showed that the total model, linear component, and 
quadratic component were all significant (Table 2.4). The analysis of variance also 
showed that there was a non-significant lack of fit which further validates the model. 
Analysis of Response Surfaces. 
Response surface graphs were plotted between two independent variables while 
remaining independent variables were kept at the zero coded level. The relationship 
between variables is illustrated by these response surface plots. 
Lycopene yield was increased with either decreased or increased ethanol volume 
(Figure 2.1A and 2.1B). At the low level of ethanol volume, predicted lycopene yield 
increased with lengthened homogenization period. This might be due to a higher cell 
concentration which allows more cells to pass through the homogenizer per unit of time, 
and therefore, more cell structures could be destroyed and more lycopene would be 
available to be extracted. On the other hand, at a higher level of ethanol volume, the 
predicted lycopene yield did not vary much with the changes of homogenization period or 
KOH volume. 
A longer homogenization period led to a higher lycopene yield (Figure 2.1A and 
2.1C), and is most likely due to enhanced rupture of tomato cell walls. In raw tomato, 
lycopene is located in the chromoplasts where it appears as crystals, needlelike structures, 
or oily droplets, depending on the tomato variety or cultivar 12. As more cell structural 
components are destroyed, lycopene should be more accessible for hexane extraction. 
In animal tissue carotenoid extraction, saponification is widely used to remove lipids 
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and results in a better separation and a less complicated extract. Therefore, the effect of 
saponification was tested in this study. The predicted yield of lycopene was increased as 
saturated KOH solution volume increased (Figure 2.1B, 2.1D, and 2.1E), but it 
decreased at the high level of KOH. Although the saponification did not significantly 
increase the lycopene yield in the regression model, the final extract was in a dried form 
instead of an oily form due to the removal of lipids. Non-oily extracts are preferential for 
better HPLC separation and reduced HPLC column obstruction. 
Hexane was used as the extraction solvent in this study. Although solvent mixtures 
which contain hexane, acetone, and ethanol have often been used in different studies and 
have been suggested to be of higher extraction efficiency 13, these mixtures also require a 
longer time to evaporate the solvent mixture than hexane. Lycopene yield increased as the 
volume of hexane and the period of vortex increased (Figure 2.1F), and similar trends 
were also observed in other studies 14,15. It is noteworthy that Periago and coworkers 13,14 
also evaluated optimizing lycopene extraction from tomato and tomato products, although 
they did not use the response surface methodology. 
Optimization and Verification. 
The optimum extraction condition was determined by the ridge maximum analysis. 
Ridge analysis generates the estimated ridge of maximum response for increasing radii 
from the center of original design 11. The ridge maximum analysis predicted that the 
conditions of ethanol 1.56 mL/g, homogenization 28 s/g, KOH solution 0.29 mL/g, 
hexane 2.49 mL/g, and vortex 17.5 s/g would lead to the maximum lycopene yield. 
The verification experiment was performed in quadruplicate on a second batch of 
tomato cells by extracting and determining lycopene content using three extraction 
conditions: our Original Method (5 mL/g of ethanol, 5 s/g of homogenization, 0 mL/g of 
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KOH solution, 6 mL/g of hexane, and 30 s/g of vortex period) 8, Central-Point Method 
(2.67 mL/g of ethanol, 20 s/g of homogenization, 0.33 mL/g of KOH solution, 2.34 mL/g 
of hexane, and 15 s/g of vortex period), and the RSM Method (1.56 mL/g of ethanol, 28 
s/g of homogenization, 0.29 mL/g of KOH solution, 2.49 mL/g of hexane, and vortex 18 
s/g of vortex period) (Figure 2.2). It was determined that the lycopene yield following the 
RSM Method was increased 3.7-fold compared to the lycopene yield using Original 
Method and 1.4-fold compared to the lycopene yield from the Central-Point Method. 
These results confirm that RSM Method conditions were significantly enhanced for 
lycopene extraction from tomato cell cultures. In conclusion, through the response 
surface methodology, the optimization of extraction procedure to maximize the lycopene 
yield from tomato cell suspension culture was achieved. The optimized conditions allow 
for over 3-fold higher yields of lycopene. 
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Table 2.1 Original and Coded Levels of Independent Variables 
    Coded   
Variable Original -2 -1 0a 1 2 
Ethanol X1 (mL/g) 1.333 2 2.667 3.333 4 
Homogenization X2 (s/g) 0 10 20 30 40 
KOH X3 (mL/g) 0 0.167 0.333 0.5 0.667 
Hexane X4 (mL/g) 1.667 2 2.333 2.667 3 
Vortex X5 (s/g) 5 10 15 20 25 
a Central point 
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Table 2.2 Experimental Design (Uncoded) and Response Values 
 Factors Response (nmol/g) 
No. X1 X2 X3 X4 X5 Observed Predicted 
1 -1 (2.000) -1 (10) -1 (0.167) -1 (2.000) 1 (20) 11 11 
2 1 (3.333) -1 (10) -1 (0.167) -1 (2.000) -1 (10) 11 11 
3 -1 (2.000) 1 (30) -1 (0.167) -1 (2.000) -1 (10) 19 20 
4 1 (3.333) 1 (30) -1 (0.167) -1 (2.000) 1 (20) 11 11 
5 -1 (2.000) -1 (10) 1 (0.500) -1 (2.000) -1 (10) 11 13 
6 1 (3.333) -1 (10) 1 (0.500) -1 (2.000) 1 (20) 9 10 
7 -1 (2.000) 1 (30) 1 (0.500) -1 (2.000) 1 (20) 19 20 
8 1 (3.333) 1 (30) 1 (0.500) -1 (2.000) -1 (10) 11 12 
9 -1 (2.000) -1 (10) -1 (0.167) 1 (2.667) -1 (10) 9 8 
10 1 (3.333) -1 (10) -1 (0.167) 1 (2.667) 1 (20) 13 11 
11 -1 (2.000) 1 (30) -1 (0.167) 1 (2.667) 1 (20) 33 31 
12 1 (3.333) 1 (30) -1 (0.167) 1 (2.667) -1 (10) 17 15 
13 -1 (2.000) -1 (10) 1 (0.500) 1 (2.667) 1 (20) 13 13 
14 1 (3.333) -1 (10) 1 (0.500) 1 (2.667) -1 (10) 8 8 
15 -1 (2.000) 1 (30) 1 (0.500) 1 (2.667) -1 (10) 18 18 
16 1 (3.333) 1 (30) 1 (0.500) 1 (2.667) 1 (20) 14 13 
17 -2 (1.333) 0 (20) 0 (0.333) 0 (2.333) 0 (15) 29 28 
18 2 (4.000) 0 (20) 0 (0.333) 0 (2.333) 0 (15) 16 17 
19 0 (2.667) -2 (0) 0 (0.333) 0 (2.333) 0 (15) 4 3 
20 0 (2.667) 2 (40) 0 (0.333) 0 (2.333) 0 (15) 16 16 
21 0 (2.667) 0 (20) -2 (0.000) 0 (2.333) 0 (15) 9 11 
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Table 2.2 (cont.) 
 Factors Response (nmol/g) 
No. X1 X2 X3 X4 X5 Observed Predicted 
22 0 (2.667) 0 (20) 2 (0.667) 0 (2.333) 0 (15) 12 9 
23 0 (2.667) 0 (20) 0 (0.333) -2 (1.667) 0 (15) 18 14 
24 0 (2.667) 0 (20) 0 (0.333) 2 (3.000) 0 (15) 14 17 
25 0 (2.667) 0 (20) 0 (0.333) 0 (2.333) -2 (5) 12 11 
26 0 (2.667) 0 (20) 0 (0.333) 0 (2.333) 2 (25) 14 15 
27 0 (2.667) 0 (20) 0 (0.333) 0 (2.333) 0 (15) 15 13 
28 0 (2.667) 0 (20) 0 (0.333) 0 (2.333) 0 (15) 10 13 
29 0 (2.667) 0 (20) 0 (0.333) 0 (2.333) 0 (15) 14 13 
30 0 (2.667) 0 (20) 0 (0.333) 0 (2.333) 0 (15) 8 13 
31 0 (2.667) 0 (20) 0 (0.333) 0 (2.333) 0 (15) 17 13 
32 0 (2.667) 0 (20) 0 (0.333) 0 (2.333) 0 (15) 15 13 
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Table 2.3 Regression Coefficients of the Predicted Quadratic Polynomial Model 
Parameter Estimate Standard Error t value p value 
A0 63.85 50.22 1.27 0.230 
A1 -17.61 12.59 -1.4 0.190 
A2 0.69 0.78 0.89 0.393 
A3 74.52 46.72 1.59 0.139 
A4 -36.09 29.63 -1.22 0.249 
A5 -0.71 1.69 -0.44 0.669 
A11 5.037 1.384 3.64 0.004 
A22 -0.009 0.006 -1.44 0.178 
A33 -27.409 22.147 -1.24 0.242 
A44 5.523 5.537 1.00 0.340 
A55 -0.006 0.025 -0.22 0.829 
A12 -0.309 0.125 -2.48 0.031 
A13 0.563 7.497 0.08 0.942 
A14 -0.844 3.749 -0.23 0.826 
A15 -0.356 0.250 -1.43 0.182 
A23 -0.563 0.500 -1.13 0.284 
A24 0.394 0.250 1.58 0.143 
A25 0.006 0.017 0.38 0.715 
A34 -19.125 14.994 -1.28 0.228 
A35 -0.375 1.000 -0.38 0.715 
A45 0.863 0.500 1.73 0.112 
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Table 2.4 Analysis of Variance for the Second –Order Response Surface Model 
Source of variation DF Sum of squares 
Model 20 891.8 b 
Linear 5 490.2 a 
Quadratic 5 214.4 b 
Cross-product 10 187.1 c 
Lack of Fit 6 63.3 c 
Pure error 5 58.8 
Total error 11 122.1 
R square 0.88  
a Significant at 1% level.  b Significant at 5% level.  c Not significant 
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A Ethanol volume (X-axis) and homogenization period (Z-axis) 
 
B KOH volume (X-axis) and ethanol volume (Z-axis) 
 
C Vortex period (X-axis) and homogenization period (Z-axis) 
 
Figure 2.1 Response surface plots showing the effects of variables in the yield of 
lycopene (nmole / g tomato cells, Y-axis).  
0
10
20
30
40
Homogeni z a t i on pe r i od ( s e c / g)
1. 33
2. 00
2. 66
3. 32
3. 98
Et hanol  vol ume ( mL/ g)
Lycopene  ( nmol / g)
0. 00
16. 67
33. 33
50. 00
4. 00
3. 33
2. 67
2. 00
1. 33
Et hanol  vol ume ( mL/ g)
0. 000
0. 167
0. 333
0. 500
0. 667
KOH vol ume  ( mL/ g)
Lycopene  ( nmol / g)
5. 00
13. 33
21. 67
30. 00
0
10
20
30
40
Homogeni z a t i on pe r i od ( s e c / g)
24. 88
19. 91
14. 94
9. 97
5. 00
Vor t ex pe r i od ( s e c / g)
Lycopene  ( nmol / g)
0. 00
6. 67
13. 33
20. 00
 54 
D Hexane volume (X-axis) and KOH volume (Z-axis) 
 
E Vortex period (X-axis) and KOH volume (Z-axis) 
 
F Vortex period (X-axis) and hexane volume (Z-axis) 
 
Figure 2.1 (cont.) 
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Figure 2.2 Effect of extraction method type on lycopene recovery from tomato cell 
culture. Different superscript letters on bars indicate significant differences between 
treatments (n=4, p<0.005, t-test). Original Method: 5 mL/g of ethanol, 5 s/g of 
homogenization, 0 mL/g of KOH solution, 6 mL/g of hexane, and 30 s/g of vortex period; 
Central-Point Method: 2.67 mL/g of ethanol, 20 s/g of homogenization, 0.33 mL/g of 
KOH solution, 2.34 mL/g of hexane, and 15 s/g of vortex period; RSM Method: 1.56 
mL/g of ethanol, 28 s/g of homogenization, 0.29 mL/g of KOH solution, 2.49 mL/g of 
hexane, and vortex 18 s/g of vortex period. 
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CHAPTER 3: 
Laboratory-Scale Production of 13C-Labeled Lycopene and Phytoene by 
Bioengineered Escherichia coli 
 
Abstract 
Consumption of tomato products has been associated with decreased risks of 
chronic diseases such as cardiovascular disease and cancer, and therefore the biological 
functions of tomato carotenoids like lycopene, phytoene and phytofluene are being 
investigated.  In order to study the absorption, distribution, metabolism and excretion 
(ADME) of these carotenoids, we tested a bioengineered Escherichia coli model for a 
laboratory-scale production of stable isotope-labeled carotenoids.  Carotenoid 
biosynthetic genes from Enterobacter agglomerans were introduced into the 
BL21Star(DE3) strain to yield lycopene.  Over 96% of accumulated lycopene was in the 
all-trans isoform, and the molecules were highly enriched with 13C by 13C-glucose 
dosing. In addition, error-prone PCR was used to create a phytoene-accumulating strain, 
which maintained the transcription of phytoene synthase (crtB). Phytoene molecules were 
also highly enriched with 13C when the 13C-glucose was the only carbon source.  The 
development of this production model will provide carotenoid researchers a source of 
labeled materials to further investigate the metabolism and biological functions of these 
carotenoids. 
 
Introduction 
Tomato consumption has been correlated with decreased risks of chronic diseases 
like prostate cancer and cardiovascular disease 1. Among many nutrients and 
phytochemicals in fresh tomatoes and tomato products, carotenoids are thought to be the 
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bioactive components responsible for disease prevention. Many epidemiology studies, 
clinical trials, animal studies, and in vitro studies have been focused on the most 
abundant tomato carotenoid, lycopene 2. However, the absorption, distribution, 
metabolism and excretion (ADME) of phytoene and phytofluene, the precursors of 
lycopene and the 2nd- and the 3rd-most abundant tomato carotenoids, have not been fully 
studied. 
As it is difficult to completely deplete the fat soluble carotenoids from humans, 
stable isotope labeled carotenoid tracers will allow a single carotenoid dose to be 
followed within pre-existing, endogenous pools. Previously, labeled lutein and !-carotene 
have been utilized to provide information regarding 1) the fraction of the ingested amount 
that is absorbed (bioavailability), 2) the fraction of that which is converted to vitamin A 
in the body (bioconversion), 3) the estimated body stores of vitamin A, and 4) the 
interaction between retinal and rhodopsin 3-8. To date, no tracer studies utilizing isotope 
labeled phytoene or phytofluene have been conducted, either in animals or humans, and 
therefore very little is known regarding the ADME of phytoene and phytofluene.  
Producing labeled phytoene and phytofluene has been a challenge to answer these 
important biomedical questions regarding phytoene and phytofluene. 
 Currently, most of the commercially pure carotenoids are produced by chemical 
synthesis, whereas a few biotechnological production systems including microalgae, 
fungi, tomato cell culture and E. coli culture are being developed and optimized. Several 
concepts for the phototrophic mass culture of algae have been proposed and compared 9-
11. Among many fungal strains, Blakeslea trispora has been employed for the production 
of natural lycopene, commercialized by Vitatene. In addition, cell suspension cultures of 
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tomato (Lycopersicon esculentum cv. VFNT cherry) has also been developed for 
laboratory scale production of phytoene, phytofluene and lycopene in our laboratory 12. 
This system was further optimized by treating cells with two bleaching herbicides, 2-(4-
chlorophenyl-thio)triethylamine (CPTA) and norflurazon. Treatment with both herbicides 
resulted in optimal production of all three carotenoids 13,14. 
It has been well known that Escherichia coli harboring carotenogenic genes from 
a Gram-negative, non-photosynthetic bacterium, Enterobacter agglomerans (or Pantoea 
agglomerans, formally Erwinia herbicola), can accumulate carotenoids (Figure 3.1). 
This carotenogenic gene cluster was first cloned from E. agglomerans in 1986 15, and the 
DNA sequence was reported in 1990 16.  Since then, novel carotenoids were produced in 
E. coli by combining different carotenoid biosynthetic genes from E. agglomerans and 
other species 17-20. Additionally, carotenoid production was tremendously improved by 
introducing the mevalonate pathway 21, increasing precursor supply 22 or by knocking out 
unnecessary genes in E. coli 23-25. Since E. coli can utilize glucose as the sole carbon 
source, this system could be used to produce isotopically-labeled carotenoids. Therefore, 
the goal of this research was to apply the carotenoid producing E. coli towards producing 
stable isotope labeled tomato carotenoids, lycopene and phytofluene, for future 
biomedical research. 
 
Materials and Methods 
Chemicals and reagents.  All bacterial strains and culture media were purchased 
from Invitrogen (Carlsbad, CA), and primers for PCR reactions were synthesized by 
Integrated DNA Technologies (Coralsville, IA). All restriction enzymes were purchased 
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from New England Biolabs (Ipswitch, MA), and molecular biology kits were purchased 
from Qiagen (Valencia, CA). All chemicals were of analytical grade and purchased from 
Sigma (St. Louis, MO), and all organic solvents were of HPLC grade and purchased from 
Fisher Scientific (Pittsburg, PA). 
Construction of truncated plasmid pAC-PTE-TR. The plasmid pAC-LYC 
(Cunningham et al. 26), which contains GGPP synthase (crtE), phytoene synthase (crtB) 
and phytoene desaturase (crtI) from E. agglomerans, was digested by restriction enzymes 
Sbf I and Bgl II (NEB), and the digested products were separated on a semi-preparative 
0.8% agarose gel.  The larger DNA fragment, containing the pACYC-184 backbone, was 
retrieved with a Qiagen Gel Extraction Kit, blunted by a NEB quick blunting kit and 
ligated by a NEB quick ligation kit. This truncated pAC-LYC, named pAC-PTE-TR 
hereafter, was amplified by E. coli strain DH5" and confirmed with electrophoresis and 
DNA sequencing by an ABI 3730XL capillary sequencer at the Roy J. Carver 
Biotechnology Center at the University of Illinois at Urbana-Champaign. 
Construction of mutated plasmid pAC-PTE-MT. GeneMorph II Random 
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) was used to create the mutant 
library.  The gene crtI was amplified by sense primer 5’- 
TGACATATGAAAAAAACCGTTGTGATTGGCGCAGGC -3’ and anti-sense primer 
5’- ATTCTCGAGTTATCAGGCTGGCGGTGGCTTTCG -3’ per the manufacturer’s 
instructions for high-error-rate PCR. The PCR products were then purified by a Qiagen 
PCR Purification Kit and mixed with pAC-LYC.  The mixture was digested by restriction 
enzymes SbfI and BglII, purified by Qiagen PCR Purification Kit, ligated by NEB Quick 
Ligation Kit, and transformed into E. coli strain DH5".  The transformants were grown 
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on LB agar plates with chloramphenicol (34 µg/mL), and white colonies were amplified 
and screened by HPLC for phytoene production.  Plasmid pAC-PTE-MT was isolated by 
a Qiagen Miniprep Kit and the selected mutated-crtI was sequenced. 
Bacterial culture in LB broth. Escherichia coli strain BL21Star(DE3) and the 
transformants were grown and maintained in LB broth supplemented with 34 µg/mL of 
chloramphenicol at 31°C, 200 rpm.  Overnight cultures were used to inoculate 5 mL 
cultures with a ratio of 1:100, and the cells were grown at 31°C, 200 rpm for 12, 18, 24 
and 48 h.  Cells were harvested by 3,220 x g centrifugation at 4°C for 10 min, washed by 
1X cold phosphate buffered saline (PBS), weighed and frozen at -80°C until further 
analysis. 
Bacterial culture in 2XM9 minimal salts media. For carotenoid accumulation 
and labeling experiments, BL21Star(DE3) and the transformants were grown in 2XM9 
media, which contains 5 g/L unlabeled or [U]-13C-glucose, 34 µg/mL of chloramphenicol 
and doubled amount of salts in 1X M9 media, except for CaCl2 and MgSO4. Overnight 
cultures from LB were used to inoculate 5 mL cultures with a ratio of 1:100, and the cells 
were grown at 31°C, 200 rpm for 12, 18, 24 and 48 h. LB broth was removed by 
centrifugation before cells were inoculated in 2XM9. Cells were harvested by 3,220 x g 
centrifugation at 4°C for 10 min, washed by 1X cold PBS, weighed and frozen at -80°C 
until further analysis. 
Analysis of glucose and acetate by HPLC. Glucose and acetate concentrations 
of culture media were determined by high performance liquid chromatography (HPLC, 
Agilent Technologies 1200 Series) equipped with a refractive index detector using a 
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Rezex ROA-Organic Acid H+ (8%) column (Phenomenex Inc., Torrance, CA).  The 
column was eluted with 0.005 N of H2SO4 at a flow rate of 0.6 mL/min at 50˚C. 
Carotenoid extraction. Bacterial cell pellets were thawed on ice, suspended in 
50 µL of deionized water and briefly vortexed to achieve homogeneous suspensions. 
Acetone (500 µL) was then added and followed immediately by a 10-s vortex period and 
5-min water-bath sonication.  A total of 200 ng of all-trans beta-carotene (DSM, Basel, 
Switzerland) was added as an internal standard, since the system did not contain any 
cyclic carotenoid.  The liquid and solid phases were then separated by 4°C centrifugation 
at 16,000 # g for 10 minutes.  The acetone/water phase was transferred to clean 
centrifuge tubes, evaporated by argon and partitioned by 500 µL of n-hexane : MTBE 
(1:1, v/v) two times. The extracts were combined and dried down under argon.  The 
samples were stored at -20°C for no more than 24 hours before HPLC analysis, with the 
entire extraction process performed under yellow light. 
Analysis of carotenoids by HPLC. The HPLC system is composed of two 
pumps (Model SD-200, Rannin Dynamax, Walnut Creek, CA), a YMC Carotenoid C30 
column (4.6#250 mm, 3 µm) with a guard column, an 18°C column oven and a 
photodiode array detector (Model 2996, Waters, Milford, MA).  The mobile phases A 
(methanol: 15% ammonium acetate aqueous solution= 98:2, v/v) and B (methanol: 
MTBE: 15% ammonium acetate aqueous solution= 8:90:2, v/v) were used, with the 
following gradient profile: 0 min, 0%B; 30 min, 100%B; 40 min, 100%B; 45 min, 0%B; 
50 min, 0%B.  Samples were reconstituted in MTBE for injection and phytoene was 
measured at 286 nm.  Phytoene standards (BASF, Ludwigshafen, Germany) were 
prepared in petroleum ether using extinction coefficient A1%, 1 cm 1250 at 286 nm. 
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Lycopene standards (DSM, Basel, Switzerland) were prepared in hexane using extinction 
coefficient A1%, 1 cm 3450 at 472 nm, and all-trans beta-carotene standards (DSM, 
Basel, Switzerland) were prepared in n-hexane using extinction coefficient A1%, 1 cm 
2592 at 452 nm. 
Mass spectrometry. Mass spectrometry was performed by the Mass 
Spectrometry Center in the School of Chemical Sciences at the University of Illinois at 
Urbana-Champaign. Unlabeled and labeled samples were purified by HPLC and 
completely dried before sample submission. The lycopene samples were dissolved in 
acetone and analyzed by Micromass Q-ToF Ultra (Waters, Milford, MA) with 
electrospray ionization positive mode (ESI+) and high-resolution scanning. The phytoene 
samples were dissolved in anisole 27 and analyzed by ThermoFinnigan LCQ Deca XP 
(Thermo Scientific, West Palm Beach, FL) with atmosphere pressure chemical ionization 
positive mode (APCI+) and low-resolution scanning. 
RNA extraction and quantitative real-time PCR of crtE and crtB. Total RNA 
was extracted from cells using Trizol (Invitrogen) per the manufacturer’s instructions.  
cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Carlsbad, CA).  mRNA expression of selected genes was measured 
via real-time PCR using SYBR Green Master Mix (Applied Biosystems).  Reactions 
were monitored by an ABI Prism 7900HT.  Primer pairs were designed to measure 
GGDP synthase (crtE) (sense: 5’-GTCAGCCCACTACCCACAAAA-3’; anti-sense: 5’-
GCGGCGATCAGACCAAAG-3’), phytoene synthase (crtB) (sense: 5’-
GATGAGGGGGTGGTGGAT-3’; anti-sense: 5’-
CAATAGCCGCATCGTCAATAATAT-3’), and 16s (rrsB) (sense: 5’-
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GCATAACGTCGCAAGACCAA-3’; anti-sense: 5’-
GCCGTTACCCCACCTACTAGCT-3’).  A validation experiment was performed on 
each set of primers to confirm efficiency and product specificity. A serial dilution was 
used to create a standard curve for quantification, and 16s was used as a housekeeping 
gene. 
Statistical analysis. Microsoft Excel for Mac 2011 was used to perform Student’s 
t-test. Figures were produced by SigmaPlot 2001. 
 
Results and Discussion 
Lycopene accumulation in BL21Star(DE3) harboring pAC-LYC 
The E. coli strain BL21Star(DE3) harboring the plasmid pAC-LYC, created by 
Cunningham et al. 26, was used for lycopene production. Prior to the labeling run, E. coli 
was maintained in LB agar or LB broth. For the labeling run, we used 2X modified M9 
minimal medium, which containing doubled nitrogen, and [U]-13C-glucose as the only 
carbon source to maintain growth characteristics of E. coli that are similar to the culture 
in LB broth. Initially, 12C-glucose was provided in the 2X M9 minimal medium at the 5 
g/L concentration to observe lycopene accumulation; we found that the glucose was 
completely depleted by 24 h (Figure 3.2A). Over 60% of glucose was used between 12 h 
and 24 h, which indicated that the cells were in the log phase, which was further 
confirmed by measuring the OD600 (data not shown) and the wet cell weight (Figure 
3.2A).  Wet cell weight reached its maximum at 24 h.  We also found that a trace amount 
of acetate was accumulated in the media at 24 h and depleted by 48 h. 
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Lycopene concentration was also measured during culture (Figure 3.2B). From a 
5 mL culture, a total of 1.4 µg lycopene was yielded, 14%, 71% and 15% of which was 
produced during 0-12 h, 12-24 h and 24-36 h, respectively. Comparing with the glucose 
concentration in the medium, E. coli seemed to continue producing lycopene even though 
the glucose had been depleted.  We suspect the metabolic intermediates, acetate, G-3-P or 
pyruvate, which supported the lycopene production, would be utilized by E. coli during 
24-36 h.  Interestingly, during the course of culture, the percentage of all-trans lycopene 
increased over time, and reached over 96% by 24 h (data not shown), which is 
representative of its level of abundance in tomatoes. Trace amount of phytoene was 
observable only from the 12 h samples, indicating that the phytoene desaturase from E. 
agglomerans was highly efficient in catalyzing the desaturation reaction, which led to the 
accumulation of the major product, lycopene. Typical chromatograms of carotenoid 
analysis are listed in the Appendix A. 
Isotopomer distribution of 13C-labeled lycopene 
High-resolution mass spectrometry was used to observe the isotopomer 
distributions of unlabeled and labeled lycopene (Figure 3.3).  HPLC purified material, 
which was handled completely plastic-free during the analysis, was ionized by 
electrospray ionization and filtered by a quadruple mass sector and a time-of-flight mass 
sector.  Under the positive mode of ionization, it was clear that the ion m/z 536.4 [M.] 
was the majority of the unlabeled lycopene, followed by the ions m/z 537.4, 538.4 and a 
few other ions ranging between m/z 546.6 and m/z 568.5. Since the natural abundance of 
13C is 1.109%, it is expectable that a few lycopene molecules naturally contained some 
13C, which resulted in the observation of ions with a higher m/z ratio.  Comparing 
! 65 
mass spectra of labeled lycopene with unlabeled lycopene, interestingly, the majority of 
ions are m/z 576.6 [M+40.], followed by the ions m/z 575.6 [M+39.], and 574.6 [M+38.], 
which indicates that the biosynthesized lycopene was mostly built from the [U]-13C-
glucose and is highly enriched with 13C. 
Error-prone PCR rescued phytoene production by maintaining crtB transcription  
In the E. agglomerans carotenogenic gene cluster, there are two promoter regions 
reported by To et al 28. One of the promoters was located within the gene crtE, and 
another was located within the gene crtI, which could result in the disruption of crtB 
transcription.  Therefore, two strategies were applied to create phytoene-accumulating 
strains: enzymatic digestion and error-prone PCR. Both methodologies were applied to 
knockout the gene crtI on pAC-LYC and to dysfunction the phytoene desaturase, 
resulting in two plasmids, pAC-PTE-TR (representing “truncated”) and pAC-PTE-MT 
(representing “mutated”), respectively (Figure 3.4A). A total of 948 base pairs of cDNA 
(65%) were removed from pAC-LYC to create pAC-PTE-TR, whereas the pAC-PTE-MT 
maintained the same length of cDNA as pAC-LYC, but had errors in crtI. The mutated 
cDNA in the pAC-PTE-MT was sequenced, and the result showed that 101 amino acids 
were deleted from the protein, and 3 amino acids were inserted to the protein by mutation 
(Figure 3.4B). 
Both plasmids were introduced into BL21Star(DE3) and the phytoene 
accumulation patterns were observed. Both plasmids resulted in phytoene accumulation, 
and both strains, which were cultured in LB broth, accumulated higher concentrations of 
carotenoids than in minimal medium.  Interestingly, E. coli harboring pAC-PTE-MT 
accumulated more phytoene than the one harboring pAC-PTE-TR (Figure 3.5).  We 
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suspected the transcription of either GGDP synthase (crtE) or phytoene synthase (crtB) 
was affected by the enzyme digestion of crtI, and therefore the real-time PCR was used to 
evaluate total RNA level of crtE or crtB among tested strains.  The RNA expression of 
crtE was slightly higher in pAC-PTE-TR compared with pAC-LYC or pAC-PTE-MT 
(Figure 3.6A), but the expression of crtB was significantly decreased (Figure 3.6B). 
In this study, we verified that the cDNA deletion of crtI reduced the mRNA 
transcription of crtB and further resulted in decreased phytoene accumulation.  Using 
error-prone PCR methodology, we generated mutated crtI that potentially maintained the 
promoter region for crtB; this mutation maintained the transcription of crtB and resulted 
in a higher phytoene accumulation compared with truncated crtI. In addition, there may 
be a polar effect between crtI and crtB in which the mRNA is more stable if the two 
genes are transcribed together. Therefore, error-prone PCR rescued phytoene production 
by maintaining crtB transcription, and the E. coli harboring pAC-PTE-MT was selected 
as the model for further 13C labeling. 
In addition, hundreds of mutant colonies were screened by UV lamp to locate a 
phytofluene-accumulating colony, but none of the colonies was identified to accumulate 
phytofluene. All screened mutants accumulated phytoene. Many studies have tested the 
diversity of products by combining crtI-type phytoene desaturases from different species 
in E. coli 29. Although the active site of phytoene desaturase from E. agglomerans has not 
been thoroughly studied, based on our error-prone PCR results, we suspect that once the 
active site is disabled, the enzyme entirely loses its function and is unable to catalyze any 
desaturation reaction. Error-prone PCR could not generate a mutated phytoene desaturase 
that only catalyzes 1, 2 or 3 steps of the desaturation cascade. 
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Phytoene accumulation in BL21Star(DE3) 
The E. coli strain BL21Star(DE3) harboring pAC-PTE-MT was grown in 2XM9 
minimal medium containing 5 g/L 12C-glucose, and its growing characteristics were 
similar to the strain harboring pAC-LYC (Figure 3.7A). Over 60% of glucose was used 
between 12 h and 24 h, and the wet cell weight reached its maximum at 24 h. The total 
phytoene accumulation per 5-mL-culture reached 836 ng by 24 h and further reached to 
896 ng by 36 h (Figure 3.7B). Interestingly, the phytoene accumulation per gram wet cell 
reached its steady state at 12 h and maintained at a similar level, indicating that phytoene 
accumulation was taking place while E. coli was growing. After E. coli reached its 
maximum cell mass, the synthesis of phytoene stopped, which is different from the 
pattern we observed with lycopene accumulation, although we also found that a trace 
amount of acetate was accumulated in the media at 24 h and depleted by 48 h. 
Phytoene synthase catalyzes a condensation reaction and yields phytoene, 
whereas phytoene desaturase catalyzes desaturation reactions and yields lycopene. In 
general, a desaturation reaction is not spontaneous but requires an energizing component. 
Unlike fatty acid desaturation, which yields an isolated double bond by NADH-
dependent hydroxylation and water abstraction, desaturation of phytoene and other 
carotenes is thermodynamically favored due to the resulting extension of the conjugated 
double bond system, which is an exergonic reaction 29. Therefore, the desaturation 
reaction might be continued even though the glucose was depleted in the media, whereas 
the condensation reaction was stopped. 
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Isotopomer distribution of 13C-labeled phytoene 
The mass spectrometry showed that the ion m/z 544.3 was the major ion for 
unlabeled phytoene, followed by m/z 545.2 and m/z 546.3 (Figure 3.8), which was 
similar to what we observed with unlabeled lycopene sample. Comparing mass spectra of 
labeled phytoene with unlabeled phytoene, we observed the majority of ions shifted to 
m/z 584.4 [M+40.], followed by the ions m/z 583.4 [M+39.], which indicates that the 
biosynthesized phytoene is enriched with 13C. Mass spectrometry of phytoene was 
performed using atmosphere pressure chemical ionization technique (APCI) under 
positive mode, which led to detectable signal but ESI did not. Similar finding was 
reported by Rivera et al. 27. 
Advantages and disadvantages of using E. coli to produce isotopically labeled 
carotenoids 
Bioengineered E. coli have the potential to generate a wide variety of carotenoids 
by combining different carotenogenic genes from different bacteria.  For example, 
combining phytoene synthase from E. agglomerans and phytoene desaturase from a 
Rhodobacter species that catalyzes only 3 steps of desaturation would generate molecules 
like beta-zeacarotene and hydroxyneurosporene, instead of lycopene 30. Furthermore, 
molecular breeding or in vitro evolution techniques have also been applied to create 
novel carotenoids in E. coli. Schmidt-Dannert et al. expressed shuffled phytoene 
desaturase and created a fully conjugated carotenoid, 3, 4, 3’, 4’-tetradehydrolycopene 19. 
The C30 pathway was also tested and a novel cyclic carotenoid, C30-diapotorulene, was 
produced 31. Therefore, by utilizing an E. coli system, labeled carotenoids with novel or 
rare structures may be easily biosynthesized. In addition, since [U]-13C-glucose is the 
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only carbon source in the minimal medium, 12C carry-over could be low, resulting in 
highly-uniformly labeled products. 
E. coli is relative easy to maintain and culture for a biosafety level-2 laboratory 
and the operation can be managed by an entry-level scientist. In addition, laboratory-scale 
production can be performed on site, which can provide freshly biosynthesized 
carotenoids to avoid oxidized or degraded contaminants. In contrast, chemical synthesis 
of carotenoids is lengthy and it requires experienced organic chemists and a sophisticated 
organic chemistry laboratory. For mass spectrometry internal standard purposes, E. coli 
produces customized labeled carotenoids in 36 h, and the purification process is relatively 
simple compared with the extractions from other biotechnological production systems, 
such as tomato cell culture 32 or microalgae 33. A table comparing the relative strengths of 
tomato cell and E. coli carotenoid production systems is listed in the Appendix B. 
However, like every biotechnological production system, by-products can be 
produced and extracted during the process, requiring further purification with liquid 
chromatography. Also, unlike chemical synthesis, it is challenging to label specific atoms 
in the biosynthesized molecules, since special labeled precursors could be costly. For this 
model system, one 5 mL culture produced 1.4 µg of 13C-labeled lycopene, which costs an 
estimated $1.25. Although this model system may not be cost-effective, research has 
been devoted to improve the carotenoid production. For examples, the supply of 
carotenoid synthesis precursor IPP had been improved by Kim et al. 34, which doubled 
the lycopene production. Introducing the mevalonate pathway resulted in a 10-fold 
increase in lycopene production 35. Gene knockout strategies have also been applied to 
improve lycopene production, resulting in a strain that can accumulate 16 mg/g of 
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lycopene 23-25. These metabolic-engineered strains could potentially make the E. coli 
system cost-effective for labeled carotenoid production. 
Summary 
Our research demonstrated that bioengineered E. coli could utilize [U]-13C-
glucose to produce highly 13C-enriched tomato carotenoids, lycopene and phytoene, and 
that error-prone PCR maintained phytoene production by maintaining the transcription of 
phytoene synthase. This production system could be further optimized and provide 
sufficient labeled carotenoids for future absorption, distribution, metabolism and 
excretion studies of carotenoids. 
 
References 
(1)  Canene-Adams, K.; Campbell, J. K.; Zaripheh, S.; Jeffery, E. H.; Erdman, Jr., J. 
W. The Tomato As a Functional Food. The Journal of Nutrition 2005, 135, 1226. 
(2)  Breemen, R. B. van; Pajkovic, N. Multitargeted therapy of cancer by lycopene. 
Cancer Letters 2008, 269, 339-51. 
(3)  Parker, R. S.; Swanson, J. E.; Marmor, B.; Goodman, K. J.; Spielman, A. B.; 
Brenna, J. T.; Viereck, S. M.; Canfield, W. K. Study of beta-carotene metabolism 
in humans using 13C-beta-carotene and high precision isotope ratio mass 
spectrometry. Annals of the New York Academy of Sciences 1993, 691, 86-95. 
(4)  Yao, L.; Liang, Y.; Trahanovsky, W. S.; Serfass, R. E.; White, W. S. Use of a 13C 
tracer to quantify the plasma appearance of a physiological dose of lutein in 
humans. Lipids 2000, 35, 339-48. 
(5)  Novotny, J. A.; Dueker, S. R.; Zech, L. A.; Clifford, A. J. Compartmental analysis 
of the dynamics of beta-carotene metabolism in an adult volunteer. Journal of 
Lipid Research 1995, 36, 1825-38. 
(6)  Tang, G.; Qin, J.; Dolnikowski, G. G.; Russell, R. M. Vitamin A equivalence of 
beta-carotene in a woman as determined by a stable isotope reference method. 
European Journal of Nutrition 2000, 39, 7-11. 
! 71 
(7)  Verdegem, P. J.; Bovee-Geurts, P. H.; Grip, W. J. de; Lugtenburg, J.; Groot, H. J. 
de Retinylidene ligand structure in bovine rhodopsin, metarhodopsin-I, and 10-
methylrhodopsin from internuclear distance measurements using 13C-labeling and 
1-D rotational resonance MAS NMR. Biochemistry 1999, 38, 11316-24. 
(8)  Lienau, A.; Glaser, T.; Tang, G.; Dolnikowski, G. G.; Grusak, M. A.; Albert, K. 
Bioavailability of lutein in humans from intrinsically labeled vegetables 
determined by LC-APCI-MS. The Journal of Nutritional Biochemistry 2003, 14, 
663–670. 
(9)  Borowitzka, M. Commercial production of microalgae: ponds, tanks, tubes and 
fermenters. Journal of Biotechnology 1999, 70, 313-321. 
(10)  Carvalho, A. P.; Meireles, L. A.; Malcata, F. X. Microalgal reactors: a review of 
enclosed system designs and performances. Biotechnology Progress 2006, 22, 
1490-506. 
(11)  Campo, J. a; García-González, M.; Guerrero, M. G. Outdoor cultivation of 
microalgae for carotenoid production: current state and perspectives. Applied 
Microbiology and Biotechnology 2007, 74, 1163-1174. 
(12)  Campbell, J. K.; Rogers, R. B.; Lila, M. A.; Erdman, Jr., J. W. Biosynthesis of 
14C-phytoene from tomato cell suspension cultures (Lycopersicon esculentum) for 
utilization in prostate cancer cell culture studies. Journal of Agricultural and Food 
Chemistry 2006, 54, 747-55. 
(13)  Engelmann, N. J.; Rogers, R. B.; Lila, M. A.; Erdman, Jr., J. W. Herbicide 
treatments alter carotenoid profiles for 14C tracer production from tomato 
(Solanum lycopersicum cv. VFNT cherry) cell cultures. Journal of Agricultural 
and Food Chemistry 2009, 57, 4614-9. 
(14)  Engelmann, N. J.; Campbell, J. K.; Rogers, R. B.; Rupassara, S. I.; Garlick, P. J.; 
Lila, M. A.; Erdman, Jr., J. W. Screening and selection of high carotenoid 
producing in vitro tomato cell culture lines for [13C]-carotenoid production. 
Journal of Agricultural and Food Chemistry 2010, 58, 9979-87. 
(15)  Perry, K. L.; Simonitch, T. A.; Harrison-Lavoie, K. J.; Liu, S. T. Cloning and 
regulation of Erwinia herbicola pigment genes. Journal of Bacteriology 1986, 168, 
607-612. 
(16)  Armstrong, G. a; Alberti, M.; Hearst, J. E. Conserved enzymes mediate the early 
reactions of carotenoid biosynthesis in nonphotosynthetic and photosynthetic 
prokaryotes. Proceedings of the National Academy of Sciences of the United States 
of America 1990, 87, 9975-9. 
! 72 
(17)  Harada, H.; Misawa, N. Novel approaches and achievements in biosynthesis of 
functional isoprenoids in Escherichia coli. Applied Microbiology and 
Biotechnology 2009, 84, 1021-31. 
(18)  Sandmann, G. Combinatorial biosynthesis of carotenoids in a heterologous host: a 
powerful approach for the biosynthesis of novel structures. Chembiochem : a 
European Journal of Chemical Biology 2002, 3, 629-35. 
(19)  Schmidt-Dannert, C.; Umeno, D.; Arnold, F. H. Molecular breeding of carotenoid 
biosynthetic pathways. Nature Biotechnology 2000, 18, 750-3. 
(20)  Umeno, D.; Tobias, A. V.; Arnold, F. H. Diversifying carotenoid biosynthetic 
pathways by directed evolution. Microbiology and Molecular Biology Reviews 
2005, 69, 51. 
(21)  Yoon, S.-H.; Lee, S.-H.; Das, A.; Ryu, H.-K.; Jang, H.-J.; Kim, J.-Y.; Oh, D.-K.; 
Keasling, J. D.; Kim, S.-W. Combinatorial expression of bacterial whole 
mevalonate pathway for the production of beta-carotene in E. coli. Journal of 
Biotechnology 2009, 140, 218-26. 
(22)  Albrecht, M.; Misawa, N.; Sandmann, G. Metabolic engineering of the terpenoid 
biosynthetic pathway of Escherichia coli for production of the carotenoids !-
carotene and zeaxanthin. Biotechnology Letters 1999, 21, 791-795. 
(23)  Alper, H.; Jin, Y.-S.; Moxley, J. F.; Stephanopoulos, G. Identifying gene targets 
for the metabolic engineering of lycopene biosynthesis in Escherichia coli. 
Metabolic Engineering 2005, 7, 155-64. 
(24)  Jin, Y.-S.; Stephanopoulos, G. Multi-dimensional gene target search for improving 
lycopene biosynthesis in Escherichia coli. Metabolic Engineering 2007, 9, 337-47. 
(25)  Alper, H.; Stephanopoulos, G. Uncovering the gene knockout landscape for 
improved lycopene production in E. coli. Applied Microbiology and Biotechnology 
2008, 78, 801-10. 
(26)  Cunningham, F. X.; Sun, Z.; Chamovitz, D.; Hirschberg, J.; Gantt, E. Molecular 
structure and enzymatic function of lycopene cyclase from the cyanobacterium 
Synechococcus sp strain PCC7942. The Plant Cell 1994, 6, 1107-21. 
(27)  Rivera, S.; Vilaró, F.; Canela, R. Determination of carotenoids by liquid 
chromatography/mass spectrometry: effect of several dopants. Analytical and 
Bioanalytical Chemistry 2011, 400, 1339-46. 
(28)  To, K. Y.; Lai, E. M.; Lee, L. Y.; Lin, T. P.; Hung, C. H.; Chen, C. L.; Chang, Y. 
S.; Liu, S. T. Analysis of the gene cluster encoding carotenoid biosynthesis in 
Erwinia herbicola Eho13. Microbiology 1994, 140, 331-9. 
! 73 
(29)  Sandmann, G. Evolution of carotene desaturation: the complication of a simple 
pathway. Archives of Biochemistry and Biophysics 2009, 483, 169-74. 
(30)  Sandmann, G.; Albrecht, M.; Schnurr, G.; Knörzer, O.; Böger, P. The 
biotechnological potential and design of novel carotenoids by gene combination in 
Escherichia coli. Trends in Biotechnology 1999, 17, 233-7. 
(31)  Lee, P. C.; Momen, A. Z. R.; Mijts, B. N.; Schmidt-Dannert, C. Biosynthesis of 
structurally novel carotenoids in Escherichia coli. Chemistry & Biology 2003, 10, 
453–462. 
(32)  Lu, C.-H.; Engelmann, N. J.; Lila, M. A.; Erdman, Jr., J. W. Optimization of 
lycopene extraction from tomato cell suspension culture by response surface 
methodology. Journal of Agricultural and Food Chemistry 2008, 56, 7710-4. 
(33)  Wilson, P. D. G.; Hilton, M. G.; Waspe, C. R.; Steer, D. C.; Wilson, D. R. 
Production of C-13-labelled beta-carotene from Dunaliella salina. Biotechnology 
Letters 1997, 19, 401-405. 
(34)  Kim, S. W.; Keasling, J. D. Metabolic engineering of the nonmevalonate 
isopentenyl diphosphate synthesis pathway in Escherichia coli enhances lycopene 
production. Biotechnology and Bioengineering 2001, 72, 408-15. 
(35)  Rodríguez-Villalón, A.; Pérez-Gil, J.; Rodríguez-Concepción, M. Carotenoid 
accumulation in bacteria with enhanced supply of isoprenoid precursors by 
upregulation of exogenous or endogenous pathways. Journal of Biotechnology 
2008, 135, 78-84.  
 
 
! 74 
 
 
 
Figure 3.1 Carotenoid synthesis pathway in Escherichia coli harboring pAC-LYC, which 
contains GGPP synthase (crtE), phytoene synthase (crtB) and phytoene desaturase (crtI). 
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Figure 3.2 Characteristics of E. coli BL21Star(DE3) harboring pAC-LYC (A) cell 
growth and the corresponding glucose concentration in 2XM9 media (B) accumulation of 
total lycopene. Data was presented as mean ± SE with n=3. 
 
 
! 76 
A 
 
 
 
B 
 
 
 
Figure 3.3 Isotopomer distribution of (A) 12C-all-trans lycopene (12C40H56, MW=536.4) 
and (B) 13C-labeled all-trans lycopene (13C40H56, MW=576.4). Measured by electrospray 
ionization positive mode in a Q-ToF mass spectrometer. 
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crtI          1 MKKTVVIGAGFGGLALAIRLQAAGIPTVLLEQRDKPGGRAYVWHDQGFTFDAGPTVITDP 
mt-crtI       1 M------------------L------T---------------------T--A-------P 
 
crtI         61 TALEALFTLAGRRMEDYVRLLPVKPFYRLCWESGKTLDYANDSAELEAQITQFNPRDVEG 
mt-crtI       7 -------S-----------L-------R-------------------AQITQFNPRDVEG 
 
crtI        121 YRRFLAYSQAVFQEGYLRLGSVPFLSFRDMLRAGPQLLKLQAWQSVYQSVSRFIEDEHLR 
mt-crtI      23 YRRFLAYSQAVFQEGYLRLGSVPFLSFRDMLRAGPQLLKLQAWQSVYQSVSRFIEDEHLR 
 
crtI        181 QAFSFHSLLVGGNPFTTSSIYTLIHALEREWGVWFPEGGTGALVNGMVKLFTDLGGEIEL 
mt-crtI      83 QAFSFHSLLVGGNPFT-SSIYTLIHALEREWGVWFPEGGTGALVNGMVKLFTDLGGEIEL 
 
crtI        241 NARVEELVV-ADNRVSQVRLADGRIFDTDAVASNADVVNTYKKLLG-HHPVGQKRAAALE 
mt-crtI     142 NARVEELVVV-DNRVSQVRLADGRIFDTDAVASNADVVNTYKKLLGLH-PVGQKRAAALE 
 
crtI        299 RKSMSNSLFVLYFGLNQPHSQLAHHTICFGPRYRELIDEIFTGSALADDFSLYLHSPCVT 
mt-crtI     200 RKSMSNSLFVLYFGLNQPHSQLAHHTICFGPRYRELIDEIFTGSALADDFSLYLHSPCVT 
 
crtI        359 DPSLAPPGCASFYVLAPVPHLGNAPLDWAQEGP-LRDRIFDYLEERYMPGLRSQLVTQRI 
mt-crtI     260 DPSLAPPGCASFYVLAPVPHLGNAPLDWAQEGPKLRDRIFDYLEERYMPGLRSQLVTQRI 
 
crtI        418 FTPADFHDTLDAHLGSAFSIEPLLTQSAWFRPHNRDSDIANLYLVGAGTHPGAGIPGVVA 
mt-crtI     320 FTPADFHDTLDAHLGSAFSIEPLLTQSAWFRPHNRDSDIANLYLVGAGTHPGAGIPGVVA 
 
crtI        478 SAKATASL 
mt-crtI     380 SAKATASL 
 
 
 
Figure 3.4 Comparison of plasmid constructs used in this study (A) phytoene desaturase 
(crtI) operons were modified by truncation or mutation (B) alignment of protein 
sequences of wild-type crtI and mutated crtI. 
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Figure 3.5 Phytoene accumulation in E. coli BL21Star(DE3) harboring pAC-PTE-TR 
and pAC-PTE-MT, cultured in LB broth. Data was presented as mean ± SD with n=2. 
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Figure 3.6 RNA expression patterns of E. coli harboring pAC-LYC, pAC-PTE-TR, and 
pAC-PTE-MT in LB broth (A) GGPP synthase (crtE) (B) phytoene synthase (crtB). Data 
was presented as mean ± SE with n=3. *p<0.05 
"!
"! "!
"!
"!
"!
! 80 
A 
 
B 
 
 
 
 
Figure 3.7 Characteristics of E. coli BL21Star(DE3) harboring pAC-PTE-MT (A) cell 
growth and corresponding glucose concentration of 2XM9 media (B) accumulation of 
total phytoene. Data was presented as mean ± SE with n=3. 
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Figure 3.8 Isotopomer distribution of (A) 12C- phytoene (12C40H64, MW=544.3) (B) 13C-
labeled phytoene (13C40H64, MW=584.4). Measured by ThermoFinnigan LCQ Deca XP 
with APCI+ interface. 
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CHAPTER 4: 
Expression, Purification and Refolding of Human Carotene-9’, 10’-Monooxygenase 
(CMO-II) in Escherichia coli 
 
Abstract 
Tomato carotenoids are lipophilic compounds that exhibit anti-oxidative activities 
and are believed to decrease the risks of cardiovascular disease and prostate cancer. Three 
mammalian carotenoid metabolizing genes have been identified, and enzymatic 
degradation has been proposed to degrade absorbed tomato carotenoids in humans. 
However, to date there is no experimental evidence to demonstrate such function of 
human carotene-9’,10’-monooxygenase (CMO-II), and therefore Escherichia coli was 
selected to express this enzyme. Full-length human CMO-II sequence and a truncated 
CMO-II were expressed, but the expressed proteins were insoluble. Tagging with NusA 
did not improve their solubility. E. coli strain Origami 2 and co-expression with 
chaperonins were also used to provide a protein-folding friendly environment, but the 
majority of CMO-II remained insoluble. Furthermore, denaturation, purification and 
refolding procedures were used to rescue CMO-II, but the refolded enzymes did not 
degrade the carotenoid substrate lutein. In conclusion, expression hosts like human cell 
lines might be better platforms in which to express soluble human CMO-II and further 
elucidate its role in carotenoid metabolism. 
 
Introduction 
Annually, the average American consumes 20.8 pounds of fresh tomatoes 
(Lycopersicon esculentum) and 71 pounds of processed tomato products 1. In a meta-
analysis of observational studies (11 case-control and 10 cohort studies), high versus low 
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intake of tomatoes was associated with an approximate 10-20% reduction in risk for 
prostate cancer 2. Also, increased plasma lycopene levels have been associated with 
reductions in cardiovascular disease (CVD) risk and have been reported to improve 
biomarkers associated with CVD 3. In fresh tomatoes and tomato products, lycopene is 
the most abundant carotenoid, followed by phytoene, phytofluene and the provitamin A 
carotenoid, !-carotene, according to the USDA National Nutrient Database. Interestingly, 
very little is known about the metabolism or degradation of phytoene, phytofluene or 
even lycopene in mammals, even though lycopene has been considered to be the main 
bioactive compound in tomatoes. 
Mechanisms including auto-oxidation 4, beta-oxidation 5 and enzymatic cleavage 6 
have been proposed to degrade lycopene in vivo. Only a few metabolites, such as 5,6-
dihydroxy-5,6-dihydrolycopene, have been detected in human plasma. It was proposed 
that lycopene may undergo in vivo oxidation to form epoxides which then may be 
converted to the polar 5,6-dihydoxy-5,6-dihydrolycopene through metabolic reduction 7. 
One human study observed 14CO2 in breath and 14C-enriched polar metabolites in urine 
from a single dose of 14C-lycopene, from which degradation via beta-oxidation was 
proposed 5. Our laboratory has observed a number of other polar products that have yet to 
be characterized, as well as identified apo-8’-lycopenal and potentially apo-12’-lycopenal 
as metabolites of lycopene in the liver of F344 rats fed lycopene 8. Similar work has also 
been done in the ferret lung, and apo-10’-lycopenol was reported as an enzymatically 
cleaved product 6. 
Three human enzymes have been suggested to interact with carotenoids, including 
retinal pigment epithelium-specific protein 65-kDa (RPE65, EC 3.1.1.64 and EC 5.2.1.7), 
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carotene-15,15’-monooxygenase (CMO-I, BCO1 or BCMO1, EC 1.14.99.36), and 
carotene-9’,10’-monooxygenase (CMO-II, BCO2 or BCDO2, no EC number assigned). 
RPE65 is an enzyme that catalyzes the conversion of retinyl esters to 11-cis-retinol 9; 
CMO-I cleaves one molecule of !-carotene to form two molecules of retinal 10; CMO-II 
has been hypothesized to cleave carotenoids including !-carotene, lycopene, lutein and 
zeaxanthin at the 9’,10’ double bond to form apo-10’ carotenoids, based on mouse 11,12 
and ferret studies 6,13. Among the same species, RPE65, CMO-I and CMO-II share 
approximately 40% overall amino acid sequence identity 14. 
The biochemical characteristics of recombinant human CMO-II have not been 
reported, but antibodies raised to human CMO-II have been produced, and 
immunocytochemistry has shown that human CMO-II is expressed in epithelial cells of 
small intestine and stomach mucosa, parenchymal cells of the liver (hepatocytes), Leydig 
and Sertoli cells of the testis, kidney tubules, the adrenal gland, exocrine pancreas cells, 
and retinal pigmented epithelium and the ciliary body of the eye. CMO-II but not CMO-I 
was detected in cardiac and skeletal muscle cells, prostate and endometrial connective 
tissue, and endocrine pancreas cells 15. Therefore, the goal of this research is to express 
human carotene-9’,10’-monooxygenase (CMO-II) in Escherichia coli and perform in 
vitro assays to elucidate the biochemical characteristics of human CMO-II. 
 
Materials and Methods 
Bacterial Strains and Vectors. The cDNA of human CMO-II was a gift from Dr. 
Stefan Andersson at the University of Texas. E. coli strains JM109(DE3), DH5alpha, 
BL21Star(DE3) and Origami 2 were purchased from Promega (Madison, WI), Invitrogen 
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(Carlsbad, CA), Invitrogen and Novagen (Gibbstown, NJ), respectively. Expression 
vectors pCOLA-Duet and pET-50(+) were purchased from Novagen, and pRSET-A,B,C 
was purchased from Invitrogen.  
Chemicals and Reagents. LB broth was purchased from Invitrogen, and primers 
for PCR reactions were synthesized by Integrated DNA Technologies (Coralsville, IA). 
All restriction enzymes were purchased from New England Biolabs (Ipswitch, MA), and 
molecular biology kits were purchased from Qiagen (Valencia, CA). Electrophoresis 
reagents were purchased from Bio-Rad (Hercules, CA), and all chemicals were of 
analytical grade and obtained from Sigma (St. Louis, MO) unless otherwise specified. 
Organic solvents were of HPLC grade and purchased from Fisher Scientific (Pittsburgh, 
PA). 
Construction of plasmids pCOLA-CMO-II and pET-CMO-II. To construct 
pCOLA-CMO-II, sense primer 5"-
GTTGAATTCGATGTTTTTTCGAGTCTTTCTCCATTTTATC-3" containing the EcoRI 
restriction site and antisense primer 5"-
ATTGCGGCCGCTCAGATGGGTATGAAGGTAC -3" containing the NotI restriction 
site were used to amplify the full length of human CMO-II (NM_031938.4). The 
amplicons were inserted to corresponding positions of vector, and transformants were 
verified by colony PCR, restriction digestion and DNA sequencing. The same 
methodology was used to construct pET-50-CMO-II, but the sense primer 5"-
AGGGAATTCTATGTTTTTTCGAGTCTTTCTCC -3" containing the EcoRI site and 
anti-sense primer 5"-TTTCGGCCGTTATCAGATGGGTATGAAGGTA -3" containing 
the EagI site were used instead. Vectors were amplified and maintained in DH5alpha. 
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Protein expression. Vectors were transformed into chemically-competent 
expression strains and selected by LB agar containing 50 µg/mL kanamycin (Sigma). 
Overnight cultures were used to inoculate LB broth at a 1:100 ratio, and cells were 
incubated at 37°C, shaken at 200 rpm until OD600 reached 0.6. Isopropyl-!-D-thio-
galactoside (IPTG) was added to induce expression, and the culture continued for specific 
culture duration. Cells were then harvested by 4°C centrifugation at 3,220 !g for 10 
minutes, washed by cold phosphate buffered saline (PBS) and stored in -80°C freezer. 
Protein extraction. Frozen cell pellets were thawed at room temperature, 
resuspended with cold lysis buffer (20 mM Tris-HCl, pH 8.5, 150 mM KCl, 0.1% Tween 
20) to make the concentration OD600 10 and then disrupted by sonication on ice (Fisher 
dismembrator, Model 100, 20% amplitude, 2 s on / 5 s off, 30 cycles).  The cell lysate 
was centrifuged at 16,000 # g for 30 min at 4 °C.  The supernatant was removed to a 
clean micro-centrifuge tube, and the insoluble fraction was resuspended in cold lysis 
buffer by sonication for further analysis. For refolding with the Novagen iFold Refolding 
System 1, the insoluble pellet was washed, denatured, dialyzed and refolded per 
manufacturer’s instructions. Protein concentrations were measured by Bio-Rad Protein 
Assay Dye using bovine serum albumin (Fisher) as a standard. 
SDS-PAGE and Western Blot. Laemmli sample buffer (Bio-Rad) and 2-
mercaptoethanol (Fisher) were added to normalized protein samples and boiled for 5 
minutes. Denatured samples were then loaded into a 10% Ready Gel and run on a Bio-
Rad electrophoresis system per manufacturer’s instruction. Completed gels were either 
stained by Coomassie blue solution or stacked with an Immobilon-P PVDF membrane 
(Millipore, Bedford, MA) for protein transfer. Primary antibody for CMO-II was 
! 87 
produced in rabbits by Dr. Xioaming Gong at the University of South Florida, and the 
secondary antibody, donkey anti-rabbit IgG, HRP linked F(ab)’, was purchased from GE 
Healthcare (Pittsburgh, PA). Chemifluorescent detection was performed with Amersham 
ECL Plus Western Blotting Detection Reagents (GE Healthcare) and detected on a Kodak 
Image Station 440CF. 
Enzyme Activity Assay. Lutein (5.688 mg) was dissolved in 1 mL of 4% Tween 
40 in acetone, and dried by argon. The dried substrates were solubilized in buffer (20 mM 
Tris–HCl, pH 8.5, 150 mM KCl, 10 µM FeSO4, 3 mM NAD+ and 0.3 mM DTT) and 
sonicated to obtain a clear micellar solution. All enzymatic assays were performed in a 
final volume of 1 mL refolding buffer containing 10 µM FeSO4, 3 mM NAD+ and 0.3 
mM DTT and 10 µg of refolded enzyme. Buffer and enzyme were pre-incubated for 5 
min at 37 °C, and then 56.8 µg of lutein in 10 µL of buffer was added to initiate the 
cleavage reaction. After incubation for 60 minutes at 37 °C in the dark, reactions were 
terminated by addition of 1.5 mL of absolute ethanol.  Incubation mixtures were 
extracted 2 times with 2.5 mL of hexane: methyl-tert butyl ether (MTBE)(1:1, v/v).  The 
combined extracts were dried by argon under yellow light, dissolved in 40 µL of MTBE 
(1:1, v/v) and analyzed by HPLC. 
HPLC analysis. The HPLC system is composed of two pumps (Model SD-200, 
Rannin Dynamax), a YMC Carotenoid C30 column (4.6#250 mm, 3 µm) with a guard 
column, an 18°C column oven and a photodiode array detector (Model 2996, Waters).  
The mobile phases A (methanol: 15% ammonium acetate aqueous solution= 98:2, v/v) 
and B (methanol: MTBE: 15% ammonium acetate aqueous solution= 8:90:2, v/v) were 
used, with the following gradient profile: 0 min, 0%B; 30 min, 100%B; 40 min, 100%B; 
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45 min, 0%B; 50 min, 0%B. Lutein standards were prepared in ethanol using extinction 
coefficient A1%, 1 cm 2550 at 445 nm. 
 
Results and Discussion 
Bioinformatics from the National Center for Biotechnology Information 
(NCBI). Human CMO-II locates on chromosome 11, location 11q.22.3-q23.1. Two 
mRNA transcripts variants were identified, isoform a (NM_031938.4) and isoform b 
(NM_001037290.1). Isoform a represents the longer transcript and it encodes a longer 
protein, whereas isoform b contains an alternate segment in the 5' UTR and uses a 
downstream start codon compared to isoform a. The resulting protein of isoform b has a 
shorter N-terminus compared to isoform a. In this study, we used isoform a 
(NP_114144.3), and the protein sequence of which is 99.3% identical to chimpanzees, 
81.4% to mice, 80.1% to rats, and 80% to cattle. To date, more than 459 SNPs have been 
reported to the database. 
Two conservative domains were identified by the Basic Local Alignment Search 
Tool (BLAST) in CMO-II isoform a: 1) residues 62-578, corresponding to RPE65 with a 
BLAST score 1119, and 2) residues 71-578 corresponding to COG3670, lignostilbene-
alpha,beta-dioxygenase and related enzymes with a BLAST score 434. Gene ontology 
predicted that CMO-II locates to an intracellular component, catalyzes 
carotene/retinal/retinoic acid metabolic processes with metal ion binding and 
oxidoreductase activities and acts on single donors with the incorporation of two atoms of 
oxygen. Sequence annotation predicted that His226, His286, His357, and His573 could 
bind to iron based on its potential similarity to CMO-I. 
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Bioinformatics from the University College London. The protein sequence of 
human CMO-II isoform a (NP_114144.3) was inputted into the prediction system, and 
the prediction was performed by the ffpred procedure on the University College London 
Bioinformatics Group website (bioinf.cs.ucl.ac.uk). The predicted secondary structure of 
CMO-II showed that 6 alpha helices and 22 beta sheets could potentially be formed in the 
structure, and 46 residues of CMO2 could be phosphorylated (Figure 4.1). None of the 
residues was predicted to be glycosylated. Residues 36-45 were predicted to be naturally 
disordered, and 7 PEST motifs were identified. PEST motifs are degradation motifs 
present in proteins involved in protein phosphorylation, protein–protein interactions and 
cell adhesion. 
Features of human CMO-II were also predicted: a molecular mass of 65,673 Da; 
molar extinction of 77,520 M$1 cm$1; isoelectric point of pH 8.55; aliphatic index of 
75.39 (CMO-II is thermally stable); charge of 16.07; half life of 30 hours; an instability 
index of 33.62 (CMO-II is stable); hydropathicity of -0.301 (CMO-II is hydrophilic); 
cytoplasmic value of 0.17; mitochondrial value of 0.74; and nuclear and peroxisomal 
values of 0.04 (CMO-II is potentially located in mitochondria). Transmembrane topology 
prediction precedue MEMSAT-SVM illustrated the residue 1-25 is a signal peptide and 
residues 290-309 are located within the membrane. The N-terminal is predicted to be in 
the extracellular space, and the C-terminal is predicted to be in the intracellular space 
(Figure 4.2). 
Initial expression of residues 1-579. The complete cDNA of NM_031938.4 was 
inserted to the vector pCOLA-Duet with a His-tag on the N-terminal (pCOLA-CMO-II) 
and expressed in the E. coli strain JM109(DE3). Expression was induced at OD600 0.6 
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with 0.1 mM IPTG, and culturing was continued at 31°C, 200 rpm, in LB broth for 2 
hours. The soluble and insoluble protein fractions were separated by sonication and 
centrifugation, and both fractions were analyzed by Western Blot. The Western Blot 
results (Figure 4.3) showed that the majority of expressed CMO-II was in an insoluble 
form, and therefore we decided to test out different culture conditions with another E. coli 
strain, BL21Star(DE3). 
Expression conditions. The combination of cultural temperature and inducer 
concentration could affect the speed of protein production and the solubility of expressed 
protein. Therefore, we decided to test two cultural temperatures, 31°C and 21°C, with 
cultural durations of 4 h or overnight. Also, we varied IPTG concentrations with 0, 0.1, 
0.5 and 1 mM. In addition, we expressed CMO-II in an E. coli strain that was specifically 
designed for protein expression due to its truncated RNase E and the lack of proteases lon 
and OmpT. The protein was analyzed by SDS-PAGE (Figure 4.4).  We observed the 
CMO-II expression in the total cell lysate fraction of all induced samples, and we 
observed similar expression patterns in all insoluble fraction samples. However, we did 
not see a similar trend of expression in the soluble fraction, which led us to a review of 
the cDNA selection and to move towards a truncation strategy. 
Truncation of CMO-II. The bioinformatics had shown that residues 1-25 
potentially form a signal peptide for CMO-II. Also, residues 36-45 were predicted to be 
naturally disordered. With residues 62-578 considered as conservative domains for 
RPE65 and COG3670, we decided to remove residues 1-62 and express residues 63-579 
with a His-tag on the N-terminal, which would yield a truncated CMO-II protein around 
58.7 kDa. Vector pRSET was used due to its suitable restriction enzyme sites. The 
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expression of truncated CMO-II was induced by 0.1 mM IPTG in the BL21Star(DE3) 
strain at 31°C for 4 hours. Protein was analyzed by SDS-PAGE, and the images showed 
that the majority of truncated CMO-II was expressed in an insoluble form (Figure 4.5). 
Comparing soluble fractions of un-induced and induced samples, we did not observe any 
thick band around 60 kDa in the induced sample. This result led us to other expression 
strategies including fusion tag, chaperone co-expression and a specialized expression 
strain Origami 2(DE3). 
Expression of CMO-II with NusA-tag. To express an insoluble protein, tagging 
the protein with a carrier peptide could potentially increase the solubility of insoluble 
protein 16. Currently, Schistosoma japonicum glutathione-S-transferase (GST), E. coli 
maltose binding protein (MBP), E. coli thioredoxin, and E. coli NusA fusion-tags have 
been implemented and are commercially available. Based on a statistical model to predict 
the solubility of protein expressed in E. coli 17, GST, MBP, thioredoxin and NusA were 
evaluated; only the NusA-tagged CMO-II was predicted to be soluble in E. coli, and 
therefore we decided to tag CMO-II with NusA. The vector pET-50(+) was selected for 
tagging the NusA to the N-terminal of CMO-II, and the fusion product was expected to 
be around 125 kDa. We observed a definitive band around 125 kDa in the insoluble 
fraction of the induced samples (Figure 4.6), and one lighter band in the insoluble 
fraction of un-induced samples, which illustrated a slightly leaky expression of NusA-
tagged CMO-II expression. We did not observe the expression of NusA-tagged CMO-II 
in the soluble fraction of either un-induced or induced samples. 
Co-expression with chaperonins of E. coli. Molecular chaperonins have been 
demonstrated to be involved in the protein folding process, and many studies have been 
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conducted to elucidate the mechanism of protein folding in E. coli 18,19. Since the 
formation of insoluble CMO-II could be due to an improper folding, we co-expressed E. 
coli chaperonins including groEL, groES, dnaK, dnaJ and grpE (pG-KJE8) with CMO-II. 
Because the sizes of these chaperonins are around 60 kDa, and their bands would stack 
with CMO-II in the SDS-PAGE analysis, we used Western Blot to detect CMO-II. The 
results (Figure 4.7) showed that the majority of expressed CMO-II was in the insoluble 
fraction, either expressed alone or expressed with chaperonins. Interestingly, co-
expressing chaperonins decreased CMO-II production. We suspect there was a 
competition for expression between CMO-II and the chaperonins. 
Expression of CMO-II in E. coli strain Origami 2 (DE3). A prediction tool, 
DiANNA 20, was used to predict the disulfide bond formation of CMO-II, and the 
analysis showed that CMO-II would contain 5 disulfide bonds in its structure to maintain 
folding. Therefore, we selected an E. coli strain Origami 2 that has mutations in both the 
thioredoxin reductase (trxB) and glutathione reductase (gor) genes, which potentially 
could enhance disulfide bond formation in the cytoplasm. The vector pCOLA-CMO-II 
was used, and the expression was induced by 0.1 mM IPTG at OD600 0.6 for 6 h at 31°C. 
The protein was analyzed by SDS-PAGE, and the image showed a definitive band around 
60 kDa in the insoluble fraction of the induced culture. When comparing soluble fractions 
between the un-induced and induced samples, no extra band was observed in the induced 
culture, which illustrated that even an environment favoring disulfide bond formation 
could not increase the CMO-II solubility in E. coli. 
Solubilization, purification and refolding of CMO-II from insoluble fraction. 
Many proteins have been expressed in E. coli in an insoluble form, and methodology has 
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been developed to denature, purify and refold these proteins into their native structure, 
regaining full biological activity 21. A systematic refolding screening tool, Novagen iFold 
refolding system 1, was used to screen suitable refolding conditions for refolding CMO-
II. A fractional factorial design was applied with this kit, and factors including pH of 
buffer (7.0, 7.5, 8.0, or 8.5), ionic strength (NaCl, 100 mM or 250 mM), detergent trap 
(methyl-beta-D-cyclodextrin 0 or 12.5 mM), redox agents (TCEP 1 mM or reduced 
glutathione/oxidized glutathione 3.8/1.2 mM) and additives (glycerol 20%, PEG6000 
0.1%, L-arginine 500 mM, guanidine hydrochloride 500 mM, CaCl2/MgCl2 1 mM or 
EDTA 1 mM) were combined on a 96-well plate for screening (Figure 4.9). 
Insoluble protein was washed, denatured by N-lauroylsarcosine, cleaned by 
dialysis and then refolded in each of the 96 buffer combinations. An absorbance of OD340 
was used to measure the precipitation of CMO-II, and we identified 6 refolding buffers 
that resulted in an OD340 that was equal to or less than 0.15, which was close to the 
background value. Interestingly, although this assay was not designed to identify key 
ingredients for proper refolding but rather to identify the combinational effects, we 
observed decreasing mean values of OD340 with increasing pH: 0.086 ± 0.019 (pH7.0) > 
0.066 ± 0.019 (pH 7.5) > 0.055 ± 0.015 (pH 8.0) > 0.036 ± 0.009 (pH 8.5). Although the 
isoelectric point of CMO-II was predicted to be at the pH 8.55, the optimum reaction pH 
of ferret CMO-II was reported to be between pH 8.0 to 8.5 6,13. From the trend of OD340 
observed in this refolding assay, our results correspond to the findings from ferret CMO-
II studies 6,13. 
Six selected buffers were as follows: 1) 50 mM Tris, 100 mM NaCl, 12.5 mM 
cyclodextrin and 1 mM CaCl2/MgCl2, pH 7.0; 2) 50 mM Tris, 1 mM TCEP and 20% 
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glycerol, pH 8.0; 3) 50 mM Tris, 100 mM NaCl and 1 mM TCEP, pH 8.0; 4) 50 mM 
Tris, 100 mM NaCl, 12.5 mM cyclodextrin and 0.1% PEG600, pH 8.0; 5) 50 mM Tris, 
12.5 mM cyclodextrin and 1 mM CaCl2/MgCl2, pH 8.5; 6) 50 mM Tris, 100 mM NaCl, 
12.5 mM cyclodextrin, 3.8/1.2 mM GSH/GSSG and 1 mM EDTA, pH 8.5. CMO-II was 
refolded in the buffers described above and tested in the enzymatic assay using lutein as 
substrate. Neither a decrease of lutein nor increase of hypothesized metabolic products 
was observed in the enzymatic assay (Figure 4.10), and therefore we suspect that the 
refolded CMO-II either still did not refold properly or could not regain its biological 
function through refolding. 
In sum, at the DNA level, regardless of whether the full-length CMO-II or 
truncated CMO-II was used, the majority of expressed CMO-II protein was insoluble, 
indicating that residues 63-579 were extremely insoluble and could not be altered by 
tagging with the extremely soluble peptide NusA. At the protein level, a friendly 
environment for protein folding like the Origami 2 strain or use of chaperonins did not 
improve the solubility of CMO-II, illustrating that E. coli might not be an appropriate 
host for expressing soluble CMO-II. Although the refolded CMO-II did not show enzyme 
activity towards lutein, other substrates like beta-carotene or lycopene could be tested in 
the future. 
Homologues of CMO-II from species other than human have been expressed and 
studied. Full-length mouse CMO-II (81.4% identical to human CMO-II) has been 
expressed using vector pBAD-TOPO in E. coli strain XL1-blue 11 and vector pTrcHis in 
E. coli strain BL21 12. Enzymatic assays in these two studies were performed using crude 
extracts of soluble protein fraction, and metabolic products of beta-carotene, lutein and 
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zeaxanthin were identified. However, no SDS-PAGE or Western Blot images were 
shown in these studies to demonstrate the enrichment of mouse CMO-II in the soluble 
fractions, and no un-induced control was used in these assays. Similar results were also 
obtained with recombinant ferret CMO-II (82% identical to human CMO-II) crude 
extract from insect cells SF9 6,13. 
To date, the only altered phenotype observed in humans due to single nucleotide 
polymorphisms (SNPs) of the CMO-II gene was altered interleukin-18 levels in plasma 
22, even though more than 459 SNPs have been reported to the database. However, many 
phenotypes in animals, like the skin color of chicken 23, milk color of cows 24, fat color of 
sheep 25 and carotenoid accumulation in tissues of knockout mice 12,26, have indicated 
CMO-II’s potential role in carotenoid degradation, directly or indirectly. It would be 
informative to observe the metabolism of carotenoids in animals overexpressing CMO-II. 
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Figure 4.1 Position dependent featured predictions of human CMO-II. Predicted by the 
University College London Bioinformatics website (bioinf.cs.ucl.ac.uk). 
 
 
 
 
 
 
 
 
Figure 4.2 Illustration of transmembrane topology prediction of human CMO-II. 
Predicted by the University College London Bioinformatics website (bioinf.cs.ucl.ac.uk). 
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Figure 4.3 Expression of human CMO-II residue 1-579 by pCOLA-CMO-II in 
JM109(DE3). Expression was induced at OD600 0.6 with 0.1 mM IPTG, and 2 h of 
culture at 31°C, 200 rpm, in LB broth. Analyzed by Western Blot. 
 
 
 
 
 
 
 
 
Figure 4.4 Combinations of cultural temperature and duration and inducer concentration 
to CMO-II expression. M: protein ladder marker top: 60 kDa and bottom: 50 kDa. There 
was a loss of insoluble fraction sample for the 21°C overnight at 0.1 mM IPTG culture, 
which resulted in a thinner band. 
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Figure 4.5 The expression of truncated CMO-II. The expression of truncated CMO-II 
was induced by 0.1 mM IPTG in the BL21Star(DE3) at 31°C for 4 hours. Protein was 
analyzed by SDS-PAGE. Lane 1: Marker; lane 2: soluble fraction, un-induced; lane 3: 
soluble fraction, induced; lane 4: insoluble fraction, induced. 
 
 
 
 
 
 
 
 
Figure 4.6 Nus-A tagged CMO-II expression with pET-50(+) in BL21Star(DE3).  Lane 
1: Marker; lane 2: soluble fraction, un-induced; lane 3: soluble fraction, induced; lane 4: 
insoluble fraction, un-induced; lane 5: insoluble fraction, induced. 
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Figure 4.7 Co-expression of human CMO-II and E. coli chaperonins. Lanes labeled with 
1 were from E. coli cells expressed CMO-II alone; lanes labeled with 2 were from E. coli 
cells co-expressed CMO-II and chaperonins (groEL, groES, dnaK, dnaJ and grpE from 
pG-KJE8). Samples were analyzed by Western Blot. 
 
 
 
 
 
 
 
Figure 4.8 Expression of CMO-II in E. coli strain Origami 2 (DE3). Lane 1: Marker; lane 
2: soluble fraction, un-induced; lane 3: soluble fraction, induced; lane 4: insoluble 
fraction, un-induced; lane 5: insoluble fraction, induced. 
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Figure 4.9 Systematic screening of CMO-II refolding buffers by the Novagen iFold 
Protein Refolding System 1. Displayed values were the absorbance of OD340, which 
corresponds to the levels of protein precipitation. 
 
 
 
Figure 4.10 HPLC chromatograms of lutein treated by refolded human CMO-II in six 
different refolding buffers. 
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CHAPTER 5: 
Summary and Future Directions 
 
 
One important question still to be answered in tomato carotenoid research is “how 
are acyclic carotenoids metabolized and excreted from our body?” While the safety of 
tomato carotenoid consumption has been established by both the 300-year presence in the 
human diet and many toxicological studies 1, we that believe both intact molecules and 
their metabolic products can impact human health 2. Therefore, this research focused 
upon developing tools to answer this question. 
Summary of Study 1. A tomato cell suspension culture was previously 
developed in our laboratory to produce 14C-labeled phytoene, phytofluene and lycopene 
for human cell culture studies and animal studies. This production model is currently 
used to produce stable isotope 13C-labeled tomato carotenoids for human 
pharmacokinetics studies. Therefore, it is important to optimize the efficiency of 
carotenoid extraction for this production system.  We applied the response surface 
methodology to optimize the extraction procedure and found optimal extraction 
conditions that enhanced yield more than 3-fold of product than the previous procedure. 
 Future directions of Study 1. In this optimization study, we focused on 
evaluating the best combination of existing factors instead of exploring a completely new 
extraction system. The solvent acetone has been proven to effectively extract carotenoids 
from many biological samples, E. coli for example. Although acetone is more difficult to 
evaporate compared with n-hexane, homogenization and saponification steps are usually 
not needed subsequently, which allows the acetone extraction method to speed up the 
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process and enable a larger scale of extraction. A purer and higher yield of tomato 
carotenoids can be expected with acetone extraction. 
Summary of Study 2. In tomato cells, lycopene and other tomato carotenoids are 
biosynthesized and exist together in a common matrix. Even though herbicides have been 
used to enrich specific carotenoid accumulation, preparative HPLC will still be needed to 
separate these similar structured compounds. Bioengineered E. coli has proven to 
accumulate carotenoids by utilizing carotenogenic genes from other bacteria, and 
resulting in highly pure end products. We provided such an E. coli strain [U]-13C-glucose 
and observed the production of 13C-labeled carotenoids. 
Future directions of Study 2. Many metabolic engineering studies have been 
done to improve the yield of carotenoids in E. coli. To make this production system cost-
effective, the labeling efficiency will need to be evaluated in the optimized strains. 
Assessment of potential commercialization could be done with a commercial laboratory. 
During this study, we screened many colonies with UV light to look for a colony 
accumulating phytofluene, but did not find one. In the future, combining the current 
system with mutated phytoene desaturase from other species like Rhodobacter might 
yield phytofluene. In addition, it is possible to express and immobilize carotenogenic 
enzymes for a cell-free continuous production. This could be an interesting new 
production system but the cost-effectiveness will need to be evaluated. 
Summary of Study 3. In the past decade, enzymatic degradation of carotenoids 
has been a hot topic in this field due to the gene cloning of RPE65, CMO-I and CMO-II. 
The biochemical characterization of human CMO-I has been completed, but to date, very 
little is known about human CMO-II. We were able to express human CMO-II in an E. 
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coli system using many complimentary methodologies, but the majority of human CMO-
II was insoluble, suggesting that human cells or insect cells might be better hosts for 
human CMO-II expression. 
Future directions of Study 3. Overexpressing human CMO-II in the human cell 
line HEK-293 could potentially yield properly folded enzymes for further biochemical 
characterization. Also, using that same system, but with the addition of a fluorescent tag 
to CMO-II, the intracellular location of human CMO-II might be discovered. With many 
different available human cell lines (Caco-2, Hep G2 or HEK-293), differential tissue-
specific accumulation could also be identified and provide valuable metabolic 
information. In addition, in the CMO-II knockout mouse model, mitochondrial oxidative 
stress has been proposed to be associated with CMO-II 3, which theoretically could be 
observed in human cell lines treated with si-RNA. Since the succinate dehydrogenase 
complex subunit D (SDHD) locates very closely with CMO-II on the chromosome 
(NCBI), knocking out CMO-II might affect SDHD expression in tissues. SDHD 
mutations have been found to cause familial paranglioma (tumors around head, neck, 
thorax and abdomen) in humans, and our laboratory has observed abnormal phenotypes 
in the fur development around the head and neck in the CMO-II knockout mouse model. 
It will be useful to measure the mRNA expression of SDHD to correlate with the 
phenotypes observed in CMO-II knockout mouse. 
In summary, this research explored suitable production systems to produce and 
extract isotopically labeled carotenoids and piloted the expression of the human enzyme 
CMO-II in E. coli. With the tools developed with this research, soon we will be able to 
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discover the details of the metabolism of tomato carotenoids and further improve the 
human health. 
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Appendix A: 
HPLC Chromatograms of Carotenoids 
 
 
 
Figure A1 HPLC chromatogram of lycopene extracted from BL21Star(DE3) harboring pAC-LYC with internal standard beta-
carotene. 
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Figure A2 HPLC chromatogram of phytoene extracted from BL21Star(DE3) harboring pAC-PTE-MT. Internal standard beta-
carotene was not shown due to its limited absorbance at 286 nm. 
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Appendix B: 
Tomato cells versus E. coli: Pros and Cons 
 
 Tomato cell culture E. coli cell culture 
Ease ++ +++ 
Speed + +++ 
Yield ++ +++ 
Application For animal and human 
studies 
Mainly for animal studies; 
potential for human studies 
upon IRB approval 
 
Note: low (+), medium (++), high (+++) !
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